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Abstract 
 
 
Kaija Kuurila. Hearing loss, balance problems and molecular defects in Osteogenesis 
imperfecta – a nationwide study in Finland. Department of Otorhinolaryngology - Head and 
Neck Surgery, University of Turku, Finland. Annales Universitatis Turkuensis, Ser. D. Tom. 
572, ISBN 951-29-2526-5, ISSN 0355-9483. Painosalama, Turku, Finland 2003. 
 
Hearing loss, bone fragility and blue sclerae are the principal clinical features in Osteogenesis 
imperfecta (OI), a genetic disorder mostly caused by mutations in type I collagen genes COL1A1 
and COL1A2. Different mutations partially explain the interindividual and intrafamilial 
variability of the disease.  
In this nationwide study on hearing in OI, 299 Finnish patients with OI were ascertained 
(prevalence 5.74/100 000). Of the 183 patients with audiometric evaluation, 46 were children and 
137 were adults. 
Hearing loss may already be present in childhood. We found hearing loss in three children. 
Subjective misjudgment of hearing ability was observed in almost 20% of adult patients. 
Hearing loss was found in 58% of adults. It affects patients with all types of OI, but tends to be 
more common in OI types I and III than in OI type IV. Sensorineural hearing loss, especially at 
an early age, may be more common in OI type I. Because the early detection and treatment of 
hearing loss is important to avoid aggravation of physical handicap, audiometry should be 
performed in all OI patients at the age of 10 years and repeated every third year thereafter.  
Vestibular dysfunction is common in OI. Inner ear damage appears to be the main reason for 
vertigo. Occasionally, vertigo is caused by basilar impression (BI), a craniocervical 
complication affecting up to 25% of OI adults. Still, some OI patients without BI or hearing loss 
also suffer from vertigo. 
Results of 43 middle ear operations were evaluated. The surgical anatomy in OI differs from 
otosclerosis especially by thick and vascular mucosa with excessive bleeding tendency, and 
elastic, fractured or atrophic stapes crura. These anatomical peculiarities cause technical 
problems, and a prerequisite for successful surgery is a correct preoperative differential 
diagnosis of OI-related hearing loss and otosclerosis. Furthermore, the hearing gain appears to 
be better after surgery centralized in units with a larger annual number of operations and more 
experienced surgeons. 
Mutations in COL1A1 or COL1A2 were found in 49 unrelated patients, representing the 
molecular genetic background of 41.1 % of the Finnish OI population. Mutation type is 
associated with OI type, while null allele mutations most often produce OI type I, and single 
base substitutions resulting in glycine substitutions in proa2(I) tend to produce OI type I and 
IV. Neither the mutated gene nor the type of mutation correlated with the presence, type or 
severity of hearing loss. The hearing loss in OI apparently is a result of multifactorial, yet 
unknown genetic and environmental effects. 
  
 
Keywords: Osteogenesis imperfecta, Hearing loss, Vertigo, Basilar impression, Middle ear 
surgery, Genotype, Phenotype, COL1A1, COL1A2, Molecular defect 
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Abbreviations 
 
 
 
ABR   auditory brainstem response 
BI  basilar impression / basilar invagination 
COL1A1  gene encoding the proα1 chains of type I collagen  
COL1A2  gene encoding the proα2 chain of type I collagen 
bp  base pair(s) 
dB  decibel 
dNTP   deoxynucleotide triphosphate 
CSGE   conformation sensitive gel electrophoresis 
DI   dentinogenesis imperfecta 
ENG   electronystagmography  
HL  hearing level 
Hz  hertz 
kb  kilobase(s)  
OAE  otoacustic emissions 
OFI  ocular fixation index 
OI   osteogenesis imperfecta  
PCR  polymerase chain reaction  
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1. Introduction 
 
Osteogenesis imperfecta (OI) is a genetic disease of connective tissue. Bone fragility 
is the main feature of OI, and it may be accompanied by blue sclerae and hearing loss. 
Short stature, bone deformities, easy bruising and reduced life span are common, and 
the dentin in teeth may be developmentally abnormal (Byers 2002; Sillence et al. 
1979b; Waltimo et al. 1996). The final outcome of OI is in some cases severe physical 
disability and secondary psychosocial deprivation and, therefore, causes considerable 
human suffering, while in the majority of cases an almost normal life may be 
achieved. OI probably affects more than 1/10 000 people. However, precise 
prevalence calculation is difficult because of unfamiliarity with the disease and poor 
reporting of some of its forms (Byers 2002; Heiberg 1983; Sillence et al. 1979b; 
Smårs 1961).  
 
Currently, OI is divided into six different types. Autosomal dominantly inherited type 
I OI is the mildest and most common form, while the most seriously affected, sporadic 
patients with type II OI usually die within the first months of life (Glorieux et al. 
2000; Glorieux et al. 2002; Hall 2002; Sillence et al. 1979b).  
 
The diagnosis of OI may be obvious at birth, but in mild forms the diagnosis may be 
delayed or the disease remains undiagnosed (Bischoff et al. 1999; Byers 2002; 
Paterson et al. 2001; Sillence et al. 1979b). Furthermore, unexplained clinical 
variability in expression has been observed within many families (Byers 2002). OI is 
mainly caused by mutations in one of the two genes, COL1A1 and COL1A2, that 
encode the synthesis of type I collagen (Heller et al. 1975; Penttinen et al. 1975; Sykes 
1993; Sykes et al. 1990). Type I collagen forms highly organized fibres and fibrils that 
provide the structural support for the body in bones, tendons, ligaments, skin, teeth 
and fasciae (Prockop et al. 1995; Vuorio et al. 1990). As a result of the mutation, the 
procollagen may be normal, but secreted in smaller amounts than normal, generally 
leading to milder phenotypes. Moreover, both normal and abnormal procollagen can 
be secreted, resulting in altered structure and a wide range of phenotypes, from 
extremely mild to lethal (Byers 2002; Sillence et al. 1979b; Wenstrup et al. 1990). 
Almost all affected families have their own private mutation (Ala-Kokko et al. 1994). 
If found, the mutation confirms the diagnosis. In addition, through the mutation, the 
pathogenesis of the disease may be further studied and understood.  
 
Hearing loss affects about half of the patients with OI (Garretsen et al. 1997; Paterson 
et al. 2001; Pedersen 1984; Stewart et al. 1989). It is reported to begin in the second to 
third decade of life, and although there are clinical similarities with otosclerosis, they 
are distinct entities (Cox et al. 1982; Garretsen et al. 1997; Holdsworth et al. 1973; 
Pedersen 1984; Quisling et al. 1979; Riedner et al. 1980). Hearing loss has been 
suggested to be more common in OI type I than IV, and the expression of hearing loss 
has been reported to vary in a family (Byers 2002; Paterson et al. 2001; Sillence et al. 
1979b). Hearing loss in OI may be treated with middle ear surgery similar to that used 
in otosclerosis. Despite the anatomical peculiarities in the middle ear in OI patients, 
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the postoperative hearing results have been encouraging, albeit not as satisfactory as in 
otosclerosis (Armstrong 1984; Cremers et al. 1991; Garretsen et al. 1990; Glasscock et 
al. 1995; Palva et al. 1977; Pedersen et al. 1983; Shea et al. 1982; Van Der Rijt & 
Cremers 2003).  
 
Balance problems have been reported as a symptom of basilar impression, a feared 
craniocervical abnormality sometimes associated with OI (Elies et al. 1980; Hayes et 
al. 1999; Pozo et al. 1984; Sawin et al. 1997; Sillence 1994). On the other hand, 
vestibular dysfunction frequently associates with otosclerosis, particularly in patients 
with sensorineural hearing loss (Cody et al. 1978; Ghorayeb et al. 1978; Igarashi et al. 
1982; Morales-Garcia 1972; Thomas et al. 1981; Virolainen 1972). 
 
There are no published studies on the possible association of molecular pathology in 
OI with different characteristics of hearing loss. 
 
Finland with its homogeneous population and advanced health care registers offers an 
excellent possibility to collect extensive data on rare disorders, and to study the 
frequency of certain symptoms in them. The aim of this study was to evaluate the 
frequency, characteristics and treatment of hearing loss in the Finnish OI population. 
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2. Review of the literature 
 
 
2.1. Osteogenesis imperfecta 
 
 
2.1.1. Historical aspects 
 
OI is a disease known to have existed since antiquity. In the beginning of the 
nineteenth century, several intact tombs dating from the 21st dynasty (c.1000 B.C.) 
were found on the east bank of the Nile in Egypt. One small painted coffin in the form 
of an Osiris figure contained bones that were suggested to be the remains of a 
mumified monkey. The bones were examined in 1967, revealing the skeleton of an 
infant with skull and long bones showing the typical appearance of OI, as well as teeth 
with manifestations of Dentinogenesis imperfecta (DI). So far, this is the oldest known 
case of OI (Gray 1969). The oldest report of bone fragility dates from the sixteenth 
century. According to Seedorff, Malbranche reported in 1678, in Traite de la 
recherché de la verité an imbecile, 20-year-old male with bones fractured in as many 
places as those of a criminal sentenced to be broken on the wheel (Seedorff 1949). 
Ekman, in his Doctoral thesis in Uppsala in 1788, presented hereditary bone fragility 
through three generations, a condition he named Osteomalacia congenita (Ekman 
1788). Association of bone fragility with blue sclerae was also reported by Axmann, 
who himself suffered from the disease (Axmann 1831). While the work of Ekman 
remained unnoticed for a long time, Lobstein received medical acclaim for 
recognizing the hereditary nature of fragile bones by describing “osteopsathyrosis 
idiopathica” in 1833 (Lobstein 1835). Vrolik presented the term “Osteogenesis 
imperfecta” in 1849, by describing an infant with large head and multiple congenital 
fractures (Figure 1) (Vrolik 1849). The three classical symptoms of OI, bone fragility, 
blue sclerae and hearing loss, were first described by Adair-Dighton in 1912 in a case 
report (Adair-Dighton 1912). This triad of OI was confirmed by van der Hoeve and de 
Kleyn in 1918, and supported by several reports during the following years (Bell 
1928; Bronson 1917; Cleminson 1926; Fraser 1919; van der Hoeve et al. 1918). 
 
Seedorff performed the first population study of OI in Denmark in 1949. He 
personally examined all the living 180 Danish patients travelling by motorcycle 
around Denmark. All patients had blue sclerae, 84% had bone fragility, and 26% 
suffered from hearing loss. Dental fragility was also reported.  Seedorff also described 
a historical person with OI, the Danish prince Ivar Boneless, who was said to have 
legs as soft as cartilage and could not walk, and therefore, he was carried into battle on 
a shield. His multiple fractures did not prevent him from conquering large parts of 
England. Unfortunately, William the Conqueror prevented a further study of his 
bones, when after his conquest he dug up the bones of Ivar Boneless and burned them 
(Seedorff 1949).  
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Figure 1. Vroliks illustration of an infant with imperfect osteogenesis. The child succumbed on 
the third day of life (Vrolik 1849). 
 
 
2.1.2. Epidemiology  
 
OI has been estimated to affect more than 1/10 000 persons, but true whole population 
studies in hearing loss in OI are scanty (Byers 2002). Prevalence numbers are 
suspected to be affected by the rarity of and unfamiliarity with the disease, as well as 
poor reporting of some forms. The perinatally lethal case may remain without 
diagnosis and the evaluation at birth may also miss the most mildly affected patients 
(Byers 2002). No racial predisposition has been found (Byers 2002; Seedorff 1949). In 
population studies on OI in Sweden, Norway and Denmark, prevalence figures 
between 3.3/100 000 and 5/100 000 have been found (Heiberg 1983; Pedersen 1983; 
Smårs 1961).  
Review of the literature 
 15 
 
 
Figure 2. A skeletal radiograph on the pelvis and femurs of a 2 -year-old boy with a recent 
diaphyseal fracture of the right femur. The type of the disease was OI type IA. 
 
In Finland, the epidemiology of OI has not been previously studied. The incidence of 
OI type I has been estimated to be 1/15 000-20 000 live births, and that of the perinatal 
lethal type OI II, 1/20 000-1/60 000 (Byers 2002). 
 
2.1.3. Clinical characteristics  
 
OI presents with various manifestations from connective tissue rich in collagen; in 
bone, tendon, ligament, skin, teeth and fasciae (Prockop et al. 1995; Vuorio et al. 
1990). The main feature of OI is bone fragility resulting in fractures caused by minor 
traumas (Figure 2). Individually, fractures may be rare or frequent, from a few 
fractures during the whole life time to hundreds already during childhood (Byers 
2002; Sillence 1988). Some 10% of the patients do not have any fractures at all 
(Sillence 1988). Short stature is common, and patients may present with secondary 
deformities in tubular bones, spine and skull (Byers 2002; Sillence 1988). In severe 
Review of the literature 
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forms, bowed limbs and kyphoscoliosis are common (Beighton et al. 1983; Engelbert 
et al. 1998; Sillence 1988). Sclerae may be intensely blue throughout life (Figure 3), 
but they may also be blue in infancy, and later pale blue or white (Sillence 1988).  
 
 
 
Figure 3. Blue sclera in a patient with OI type I. 
 
Hearing loss affects about half of the patients with OI (Garretsen et al. 1991a; 
Paterson et al. 2001; Pedersen 1984; Quisling et al. 1979; Riedner et al. 1980; Sillence 
et al. 1979b; Stewart et al. 1989). The organic dentin matrix in teeth can be 
developmentally aberrant. The affected teeth appear discolored and exhibit fragility 
due to the poor mineralization of the dentin. This condition has been designated as 
Dentinogenesis imperfecta (DI type I, Figure 4) (Shields et al. 1973). However, the 
severity of dentinal manifestations in patients with OI apparently forms a continuum 
from seemingly normal dentin structure to severe DI. (Waltimo et al. 1996). Joint 
hypermobility is common, and dislocations and herniae may occur, as well as easy 
bruising, increased sweating and heat intolerance (Byers 2002; Engelbert et al. 1998; 
Sillence 1988). Frontal and temporal bossing may contribute to the triangular face 
typical for OI, and Wormian bones or the radiographic bony islands in the occipital 
and parietal area contribute to the softness of the skull in childhood (Sillence 1988). 
Basilar impression may occur (Engelbert et al. 1998; Sillence 1994). In severe forms 
of OI, the life span is reduced (Byers 2002; Paterson et al. 1996).   
 
 
 
Figure 4. Visually apparent Dentinogenesis imperfecta in a patient with type IV OI. 
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2.1.4. Classification 
 
Until the 1970´s, a classification of OI introduced in 1906 by Looser was used (Looser 
1906). He suggested that the hereditary idiopathic bone fragility, Osteogenesis 
imperfecta, presented by Vrolik in 1849, and the congenital bone fragility named as 
Osteopsathyrosis idiopathica by Lobstein in 1833, would be one disease entity which 
may appear with two distinct variants of severity: OI congenita with fractures at birth 
(Vroliks disease), and OI tarda with fractures first some months or years after the birth 
(Lobsteins disease) (Lobstein 1835; Looser 1906; Vrolik 1849). 
 
Sillence introduced the classification of OI currently in use in 1979. It was based on 
clinical and radiographic criteria and the mode of inheritance (Sillence et al. 1978; 
Sillence et al. 1979a; Sillence et al. 1979b). Later, this classification has been 
modified on several occasions (Table 1) (Glorieux et al. 2000; Glorieux et al. 2002; 
Hall 2002; Sillence 1981; Sillence 1988). However, the wide spectrum of the disease, 
as well as considerable interfamilial and intrafamilial variability often make 
classifications difficult (Primorac et al. 2001). 
 
In sporadic cases it may be clinically impossible to distinguish severely affected type 
IV from type III, or type IV cases from types I and III (Sillence 1981).  
 
The catalogue of human genes and genetic disorders, Online Mendelian Inheritance of 
Man, lists 60 OMIM entries under the diagnosis of Osteogenesis imperfecta. This fact 
indicates that there is no universally accepted diagnostic classification of OI at the 
present time. Therefore, in this thesis the numbers of the OMIM entries have been 
used with the types of OI in the Sillence classification, only (Online Mendelian 
Inheritance in Man 2000). 
 
 
2.1.4.1. Osteogenesis imperfecta type I (OMIM 166200) 
 
OI type I is the most common form of OI. Sclerae are distinctly blue and hearing loss 
is common. Fractures may present already at birth or in the perinatal period, but they 
usually appear when the child begins to walk. Bone fragility is often quite constant 
during childhood, decreases after puberty, and increases again after the menopause in 
women and in the sixth to eighth decade in men. However, some patients with OI type 
I have no fractures. The fractures mostly affect the long bones, ribs and the small 
bones of hands and feet. Skeletal deformities may appear, but the long bone deformity 
is not as severe as in other types of OI. Hyperextensibility of ligaments, bowing and 
angulation due to fractures and deformities at the knees and in the feet may appear. 
Kyphosis or scoliosis may occur in some patients. Easy bruising is common. Type I 
OI is further divided into subgroups A and B, based on visual absence (A) or presence 
(B) of DI (Byers 2002; Sillence 1988; Sillence & Rimoin 1978; Sillence et al. 1979b).  
The inheritance is autosomal dominant (Sillence et al. 1979b). 
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Table 1. The Sillence classification of Osteogenesis imperfecta, discussed and modified at the 
8th International Conference on Osteogenesis imperfecta, Annecy, 2002 (Glorieux et al. 2000; 
Glorieux et al. 2002; Hall 2002; Sillence 1981) .   AD, Autosomal Dominant; AR, Autosomal 
Recessive 
 
OI Type Clinical features              Inheritance 
 
IA Mild to severe bone fragility;                                 AD 
                      normal or slightly short stature,        
 intensely blue sclerae, presenile hearing loss,  
                      normal teeth 
 
IB Mild to severe bone fragility;                    AD 
                      normal or slightly short stature,                              
                      intensely blue sclerae, presenile hearing loss, DI 
 
II Extremely severe bone fragility, lethal                AR/AD 
 
III Variable, often severe bone fragility                AR/AD 
 in infancy with progressive skeletal  
                      deformity; short stature,bluish sclerae,  
                       variable dentin abnormality 
 
IVA Bone fragility with mild to moderate deformity,             AD                              
                      often short stature, normal sclerae, normal teeth 
 
IVB Bone fragility with mild to moderate deformity,             AD 
                     often short stature normal sclerae, DI 
 
V At least one episode of hyperplastic callus formation,    AD 
                     moderate to severe fragility of long bones and  
                      vertebral bodies, limitations of pronation/supination  
                      in forearms, ligamentous laxity, white sclerae,  
                       normal teeth  
                      
VI  Vertebral compression fractures,                                      ? 
                      moderate to severe bone fragility,  
                      white or faintly blue sclerae, normal teeth  
                             
Other types 
 Cole-Carpenter – OI type                   AD 
 Bruck  - OI type                                          AR 
 North American OI                    AR 
 Osteoporosis-pseudoglioma syndrome                   AR 
 Additional undefined types 
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2.1.4.2. Osteogenesis imperfecta type II (OMIM 166210) 
 
This perinatally lethal type of OI presents with severe osseous fragility and defective 
ossification, and most often leads to death in utero or within the first months of life. 
Survival beyond one year is extremely rare (Sillence et al. 1984; Sillence & Rimoin 
1978). Sillence has divided this OI type with almost black sclerae into 3 groups on the 
basis of differences in clinical and radiographic findings. In group A, the babies are 
small for gestational age and prematurity is common. Some 20% are stillborn, and the 
remainers die within hours to days after birth. The skull is large, and skull and face are 
molded. Limbs are short, broad and crumpled, and ribs are continuously beaded. 
Group B presents with short, broad, crumpled femora, angulation of tibiae but normal 
ribs or ribs with incontinuous beading. Respiratory distress is not so severe as in group 
A, and some children may survive for several years. Group C is rare. The babies are 
small for gestational age, stillborn or die in the newborn period. Long bones are thin, 
rectangular and inadequately modelled with multiple fractures, and ribs are thin and 
bent (Sillence 1988; Sillence et al. 1984).  
 
Most cases are sporadic and due to new dominant mutations (Hall 2002; Sillence 
1988; Sillence et al. 1984). The rare recurrences in healthy parents may be caused by 
recessive forms or parenteral mosaicism (Sillence et al. 1984). 
 
2.1.4.3. Osteogenesis imperfecta type III (OMIM 259420) 
 
The progressive deforming type of OI most often presents with a phenotype 
recognized at birth by short stature and deformities resulting from in utero fractures. 
Fractures may also appear first during the first years of life caused by minimal trauma, 
mostly in long bones and ribs. The fracture frequency in OI type III is highest of all 
those with OI, and 200 fractures during the lifetime is common. Bowing, angulation 
and rotatory deformation of an abnormally malleable skeleton lead to deformities of 
the upper and lower limbs (Figure 5). Sclerae are often pale blue at birth and generally 
become normal by puberty.  Severe kyphoscoliosis is common, as are increased 
sweating and heat intolerance. In adulthood the stature is short, and DI is common 
(Sillence 1988; Sillence & Rimoin 1978; Sillence et al. 1979b). Hearing loss is 
thought to be uncommon (Sillence et al. 1979b). Differentiating between OI type III 
patients and those with a milder form of perinatally lethal OI type II may sometimes 
be difficult (Sillence et al. 1986). The inheritance is autosomal dominant or recessive, 
and parenteral mosaicism occurs (Byers 2002; Hall 2002). 
 
 
2.1.4.4. Osteogenesis imperfecta type IV (OMIM 166220) 
 
OI type IV is clinically more heterogeneous than the other subtypes of OI, and distinct 
subtypes have been separated from this entity in recent years (Glorieux et al. 2000; 
Glorieux et al. 2002). The expression and deformity of long bones are extremely 
variable (Sillence & Rimoin 1978; Sillence et al. 1979b). The stature is generally short 
in adulthood, although it may be normal at birth. Sclerae are either normal or bluish at 
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birth, and become normal in childhood or by adulthood. About 25% of the children 
have fractures at birth. The fracture frequency and total number of fractures during 
specific age periods are variable, but maximal in childhood with marked reduction 
after puberty and into adult life. Scoliosis is seen in one-third of the patients. No 
marked tendency to nosebleeds or easy bruising appears. Hearing loss is assumed to 
be less common than in OI type I, and, when presented in a family, it may vary in 
expression (Sillence et al. 1979b). Joint hypermobility and dislocations are common. 
Type IV OI is further divided into subgroups A and B, based on absence (A) or 
presence (B) of DI (Byers 2002; Sillence 1988). The inheritance is autosomal 
dominant. 
 
 
 
Figure 5.  A skeletal radiograph on the 
right femur and tibia of a 6-month-old 
boy with severe OI type III. He was the 
first child of healthy parents, and had 
multiple congenital fractures. The 
fracture of the femur has been healing 
but left the bone thickened and 
deformed. In the tibia there was no 
fracture but the curved anterior 
deformation developed after birth 
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2.1.4.5. Osteogenesis imperfecta type V 
 
Glorieux and co-workers reported in 2000 on a group of patients earlier classified as 
OI type IV, with a history of moderate to severe increased fragility of long bones and 
vertebral bodies but at least one episode of hyperplastic callus formation. All patients 
had limitations in the range of pronation/supination in one or both forearms, 
associated with a radiologically apparent calcification of the interosseous membrane. 
None of the type V patients presented with blue sclerae or DI, but ligamentous laxity 
was similar to that in patients with OI type IV. Autosomal dominant inheritance was 
reported (Glorieux et al. 2000). 
 
 
2.1.4.6. Osteogenesis imperfecta type VI 
 
In a study in 2002, another group of patients initially diagnosed as OI type IV was 
reported by Glorieux and co-workers. Fractures were first documented between 4 and 
18 months of age, and they were more frequent than in patients with OI type IV. 
Sclerae were white or faintly blue and DI was uniformly absent. All patients had 
vertebral compression fractures. Mutation screening of the coding regions and 
exon/intron boundaries of both collagen type I genes did not reveal any mutations, 
type I collagen protein analyses were normal, and, so far, the pattern of inheritance has 
not been ascertained (Glorieux et al. 2002). 
 
 
2.1.4.7. Bone fragility related disorders 
 
In addition to the previous classification of OI, other more infrequent dysplasias with 
decreased bone density have been reported and included under the diagnosis OI (Hall 
2002). The molecular pathology of these diseases is unknown. Cole-Carpenter 
dysplasia (OMIM 112240) is a sporadic condition with bone deformities and multiple 
fractures as in OI, but it also includes ocular proptosis with orbital craniosynostosis, 
hydrocephalus, and distinctive facial features (Cole et al. 1987). Bruck reported, in 
1897, a patient with multiple joint contractures and OI. Only a few patients with this 
condition, later named Bruck syndrome (OMIM 259450), have been reported since 
then, with flexion contractures and recurrent fractures leading to severe deformity, 
short stature and kyphoscoliosis, white sclerae and normal hearing (Bruck 1897; 
McPherson et al. 1997). Autosomal dominant inheritence has been found in Bruck 
dysplasia I, but the inheritance in type II still is unknown (Hall 2002). Osteoporosis-
Pseudoglioma dysplasia (OMIM 259770) or the ocular form of OI is an autosomal 
recessive condition due to mutations in the LRP5 gene (Gong et al. 2001). Singleton-
Merton dysplasia, Osteopenia with radiolucent lesions of the mandible (OMIM 
166260), Geroderma osteodysplasticum (OMIM 231070) and Idiopathic juvenile 
osteoporosis (OMIM 259750) are additional rare syndromes sharing similar skeletal 
symptoms with OI (Hall 2002).  
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2.1.5. Genetics and molecular pathology 
 
OI is a disease with both autosomal dominant and recessive modes of familial 
inheritance (Byers 2002; Sillence et al. 1979b). There are sporadic cases caused by 
new mutations (Byers 2002). There is also growing evidence for parental mosaicism. 
This situation poses a difficult task for the clinical geneticist in genetic counseling, as 
a mosaic parent may appear clinically healthy but may carry the mutation in a fraction 
of the gonadal cells and thus he or she is at a risk of having another affected child 
(Raghunath et al. 1995). 
 
Since the first evidence of the association between collagen defects and OI in 1975, 
when skin fibroblasts of a fetus with perinatally lethal OI were found to have 
decreased synthesis of type I collagen, it has become evident that in at least 90% of 
the cases OI is caused by mutations in genes that encode the type I procollagen (Heller 
et al. 1975; Penttinen et al. 1975; Sykes 1993; Sykes et al. 1990). To date, over 20 
collagen types have been identified (Myllyharju et al. 2001). The collagens constitute 
a family of related proteins that are assembled in a variety of supramolecular 
aggregates with a structural function in the extracellular matrix (Vuorio & de 
Crombrugghe 1990). On the basis of protein and gene structures, type I collagen is 
included in the fibril-forming group of collagens, likewise collagens II, III, V and XI. 
By forming highly organized fibres and fibrils type I collagen provides the structural 
support for the body in bone, tendon, ligament, skin, teeth and fasciae (Prockop & 
Kivirikko 1995; Vuorio & de Crombrugghe 1990). 
 
Type I collagen is a helicotrimer of two identical a1(I) chains and one a 1(II) chain. 
The a -chains are synthetized as precursor-pro a -chains with amino- and carboxy-
terminal extensions, referred to as N- and C-propeptides. After a number of 
posttranslational modifications, three pro a -chains associate through their C-
propeptides and fold into a triple-helical procollagen molecule. Extracellularly, 
specific C- and N-proteases remove the propeptides, and the remaining collagen 
molecule consists of the triple-helical domain and short N- and C-telopeptid 
propeptides (Vuorio & de Crombrugghe 1990). 
 
The human COL1A1 gene is located in chromosome 17 (17q21.3-q22), while the 
location of the COL1A2 gene is in chromosome 7 (7q21.3-q22). The COL1A1 gene is 
about 18 kb in length with 51 exons, and the COL1A2 gene is about 38 kb in length 
and consists of 52 exons (Chu et al. 1984; Huerre et al. 1982). Hundreds of mutations 
in these two genes have been detected in OI patients so far (Kuivaniemi et al. 1997; 
Prockop et al. 1990).  The types of mutations present a wide array: single base-pair 
mutations resulting in substitution of obligatory glycine residues, deletions and 
insertions, null allele mutations, splicing mutations, mutations in the carboxyl-terminal 
propeptide interfering with molecular assembly and multiexon rearrangements (Byers 
et al. 1991; Kuivaniemi et al. 1997; Prockop et al. 1990). 
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As a result of the mutation, the procollagen may either be normal, but secreted in 
smaller amounts than normal, or both normal and abnormal procollagen can be 
secreted (Byers 2002; Wenstrup et al. 1990). Generally, normal structure of the 
molecules in reduced amount leads to milder phenotypes, and an altered structure to a 
wider range of phenotypes, from extremely mild to lethal (Sillence et al. 1979b; 
Wenstrup et al. 1990). Although most of the mutations are unique for a family with 
OI, the same mutations have occasionally been found in unrelated individuals 
(Pruchno et al. 1991). 
 
Most mutations in the mildest variant, type I OI, cause decreased expression of 
proa1(I)-chains because of either premature-termination codons or RNA-splicing 
defects in the COL1A1 gene. On the other hand, the most severe variants of OI, OI 
types II, III and IV, are primarily caused by single-base substitutions that convert a 
codon for an obligate glycine in the triple helix of the protein into a codon for an 
amino acid with a bulkier side chain that distorts the conformation of the triple helix 
(Barsh et al. 1982; Korkko et al. 1997; Redford-Badwal et al. 1996; Willing et al. 
1992).  
 
The underlying genetic defect of the new OI types V and VI remains to be elucidated, 
since no evidence of mutations has been found in type I collagen (Glorieux et al. 2000; 
Glorieux et al. 2002). 
 
2.1.6. Diagnosis 
 
Medical and family history, clinical examination and skeletal radiographs are still the 
benchmarks for the diagnosis of OI (Byers 2002). 
 
OI type I is often suspected because of family history or a finding of blue sclerae in a 
patient with recurrent fractures. In a child with otherwise normal body habitus, OI is 
an important differential diagnosis for child abuse (Byers 2002; Paterson et al. 1993). 
Mild forms of type I OI may remain undetected, and in unclear or atypical 
postmenopausal osteoporosis this diagnosis should be considered (Bischoff et al. 
1999). 
 
OI type II is obvious at birth, and may be detectable already during the pregnancy by 
fetal ultrasonography. The diagnosis can be confirmed by fetal radiographs showing 
poor calcification and deformities of the skeleton, sometimes with no evidence of 
skeletal structures (Byers 2002; Heller et al. 1975; Shapiro et al. 1982a). 
 
OI type III is often recognized in the perinatal period, while fractures or deformity 
may be present at birth. Some patients, however, have only mild femoral bowing and 
the fracture rate may be variable. Radiographs may reveal undermineralized calvarium 
with large anterior fontanelle and bony islands of the skull, i.e. so-called Wormian 
bones, and thin and gracile ribs and long bones with evidence of intrauterine fractures. 
If no fractures are present at birth, they usually appear during the first year of life 
caused by minimal trauma (Byers 2002). 
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OI type IV is in most cases identified in early infancy by fractures in utero or at birth. 
The diagnosis may be delayed if the fractures are healed, no deformity appears, and no 
X-ray is taken. The children may also present with only bowing of extremities at birth, 
with no fractures (Byers 2002). Types V and VI OI may be distinguished from OI type 
IV by hyperplastic callus or vertebral compression fractures (Glorieux et al. 2000; 
Glorieux et al. 2002). 
 
DI can be helpful in diagnosis of OI, although a similar-appearing aberration that 
affects dentin only, DI type II, also exists. (Shields et al. 1973) The marked variation 
in the severity of the dentinal manifestations of OI makes the diagnosis based on 
dental findings still more complicated. (Waltimo et al. 1996). 
 
In the absence of family history or obvious diagnosis, a study of collagen synthesis by 
dermal fibroblasts may be performed (Byers 2002; Holbrook et al. 1989; Wenstrup et 
al. 1990). Mutations in COL1A1 and COL1A2 genes may also be identified by 
analysis of genomic DNA, or in expressed sequences using cDNA made from mRNA 
(Korkko et al. 1998a; Korkko et al. 1997).  
 
 
2.1.7. Treatment  
 
Until recently, the treatment of OI has been focused on preventing fractures, reducing 
deformities and promoting normal function, as well as on early supportive 
physiotherapy to maximize the muscular strength and minimize the inactivity and 
deformity (Byers 2002; Primorac et al. 2001). Intramedullary rods, especially Bailey-
Dubow and Soffield type elongating rods, are commonly used in treatment of children 
with OI (Primorac et al. 2001). Fractures may also be treated with the usual orthopedic 
care (Byers 2002). Scoliosis may be treated with a brace, and operative treatment is 
recommended when the deformity is progressive, pain-causing scoliosis. However, the 
orthopedic treatment of scoliosis is usually most difficult (Primorac et al. 2001). 
 
The dental treatment largely depends on the degree of tooth involvement. The major 
task during primary dentition is to ensure favourable conditions for the eruption of the 
permanent teeth, and later to retain the occlusal function. Therefore, teeth are often 
treated with composite fillings, and preferably with temporary stainless steel crowns 
and permanent prosthetic crowns to maintain their vertical height (Ranta et al. 1993).  
 
A number of medical therapies have been attempted for patients with OI. Anabolic 
steroids have been helpful but because of their adverse side effects they are not in use. 
Fluoride and magnesium oxide have not been shown to be effective. Calcitonin has 
been reported to give some subjective relief for pain (Castells 1973). Recently, most 
encouraging results in the treatment of patients with bisphosphates have been reported 
by several groups (Adami et al. 2003; Batch et al. 2003; Falk et al. 2003; Glorieux 
2000; Glorieux 2001; Glorieux et al. 1998; Primorac et al. 2001; Zeitlin et al. 2003). 
The bisphosphonates constitute a group of synthetic analogues of pyrophosphate, and 
they possess a remarkably variable range of effectiveness, e.g. inhibiting bone 
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resorption. Cyclic intravenous treatment with pamidronate (3-amino-1-
hydroxypropylidene-bisphophonate) has been proved to be beneficial in treatment of 
children with OI, leading to increased bone mineral density and increased physical 
activity (Falk et al. 2003; Primorac et al. 2001; Zeitlin et al. 2003). In adults, 
intravenous Neridronate has significantly increased bone mineral density and lowered 
the risk of clinical fracture(Adami et al. 2003). Therefore, bisphosphonate therapy 
seems to provide clinical benefits, not only in children with OI, but also in adults. 
Effects of bisphosphonates on hearing thresholds in OI have not been reported. In 
otosclerosis, however, there are controversial reports of effects of bisphosphonates: 
On the one hand, a trend toward stabilization or improvement in air and bone 
conduction thresholds as well as improvement in neurotological symptoms, and, on 
the other hand, severe deterioration of pure tone thresholds (Boumans et al. 1991; 
Brookler et al. 1997; Kennedy et al. 1993; Yasil et al. 1998). 
 
Growth hormone has been reported to cause increased bone formation rate and 
density, and decreased fracture rates, in children with OI (Marini et al. 2003). Also 
gene therapy has been studied, in order to reintroduce modified cells capable of 
homing to bone and participating in new bone formation into the host, and thereby 
correcting the underlying genetic mutation (Primorac et al. 2001). 
 
 
2.2. Hearing loss in Osteogenesis imperfecta 
 
2.2.1. Definition 
 
Six population studies on OI have been published so far, with great variation in the 
definition of the hearing loss (Paterson et al. 2001; Pedersen 1983; Seedorff 1949; 
Sillence 1981; Smårs 1961; Stewart & O'Reilly 1989). Three of these population 
studies have focused on hearing loss (Paterson et al. 2001; Pedersen 1984; Stewart & 
O'Reilly 1989). Definition of the hearing loss has been presented in two of them 
(Pedersen 1983; Stewart & O'Reilly 1989). In the Danish study by Pedersen a pure 
tone audiometry with air and bone conduction measurement at frequencies 250, 500, 
1000, 2000 and 4000 Hz was used. Sensorineural hearing loss was defined as air 
conduction thresholds for one or more of these frequencies greater than 15dB(HL) and 
an air-bone gap of less than 15 dB. Conductive hearing loss was defined as an air-bone 
gap of 15 dB or greater and a bone conduction threshold of less than 15 dB at one or 
more of these frequencies, while mixed hearing loss was defined as a bone conduction 
level greater than 15 dB and an air-bone gap of 15 dB or greater at one or more of the 
frequencies 250-4000 Hz (Pedersen 1984). In the Scottish study, the sensorineural 
hearing loss was defined as pure tone hearing thresholds of 30dB(HL)or greater at two 
or more of the octave frequencies 250-8000 Hz, conductive hearing loss as an air-bone 
gap of 15 dB or greater at two or more of these frequencies, and mixed hearing loss as 
a bone conduction level of 30dB or greater and an air-bone gap of 15 dB or greater at 
two or more of the frequencies 250-8000 Hz (Stewart & O'Reilly 1989). In the recent 
Scottish study by Paterson, symptomatic hearing loss was recorded (Paterson et al. 
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2001). In the study by Sillence presenting the classification of OI no definition of 
hearing loss was given, nor was it given in the Danish study from 1949, while a 
hearing test with a whispering voice was used in the Swedish study (Seedorff 1949; 
Sillence et al. 1979b; Smårs 1961).  
 
In addition to the population studies, a major study on hearing loss in OI type I was 
performed by Garretsen and co-workers in the Netherlands in the 1990´s. Conductive 
hearing loss was defined as the average air-bone gap for the frequencies 500, 1000 and 
2000 Hz, or else the average air-bone gap at 4000 and 8000 Hz greater than 15 dB 
with a corresponding bone conduction threshold below 15 dB. Sensorineural hearing 
loss was defined as the average air conduction threshold equal to or greater than 15 dB 
for the frequencies mentioned above, and a corresponding air-bone gap smaller than 
15 dB, and mixed hearing loss as the average air-bone gap equal to or greater than 15 
dB with a corresponding bone conduction threshold equal to or greater than 15 dB 
(Garretsen et al. 1997). These definitions paralleled the definitions used by Pedersen 
in the population study in Denmark, and the definition given by Shapiro in 1982 in a 
study of 55 patients with OI. Normal hearing was defined as less than 15 dB drop at 
frequencies 250 to 8000 Hz, and conductive hearing loss as a 15 dB or greater 
decrease in air conduction compared to bone conduction thresholds at one or more of 
these frequencies. Sensorineural loss was defined as a depression in both air and bone 
conduction threshold without an air-bone gap, and mixed hearing loss as involving 
features from both conductive and sensorineural hearing loss, usually with a 
prominent air-bone gap (Shapiro et al. 1982b).  
 
 
2.2.2. Epidemiology 
 
In population studies, which include systematic audiological investigations on OI, 
hearing loss has been reported in up to 58% of the patients (Pedersen 1984; Stewart & 
O'Reilly 1989).  In a Danish population study with 201 OI patients, presented by 
Pedersen in 1984, hearing loss was found in half of the audiologically tested ears 
(Pedersen 1984). In Scotland, Stewart and O’Reilly found hearing loss in 58% of the 
53 patients (Stewart & O'Reilly 1989). Of the previous studies focusing on hearing 
loss in classified types of OI, Sillence in 1979 and 1988, as well as Paterson in 2001, 
included all types of OI, while Garretsen in 1991 and 1997 included OI type I, only. 
Hearing loss has been reported to be most common in OI type I, affecting 35-78% of 
patients, and it has been thought to be less common in OI type IV. In OI type III, 
Sillence found only 1 out of 6 patients with hearing loss, whereas Paterson reported 
hearing loss in 52% of 207 patients (Garretsen et al. 1997; Garretsen & Cremers 
1991a; Paterson et al. 2001; Sillence 1988; Sillence et al. 1979b). The definition of 
hearing loss, however, has varied greatly in the studies referred to, and the study 
subjects may have been selected, like in Garretsen´s study from 1991, consisting of 
only type I OI patients, or, as in the study from 1997, of type I OI patients who either 
were elected for ear surgery or volunteered for the study because of their hearing loss 
(Garretsen et al. 1997; Garretsen & Cremers 1991a). 
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2.2.3. General characteristics and etiology 
 
The hearing loss in OI most often begins in early adulthood, in the second to third 
decade of life, although it may sometimes begin in the first decade of life. The hearing 
loss is progressive, and often proceeds from conductive hearing loss to a mixed and 
sensorineural type with increasing age (Cox et al. 1982; Garretsen et al. 1997; 
Pedersen 1984; Quisling et al. 1979; Riedner et al. 1980). Mixed hearing loss, on the 
other hand, has been reported as the most frequent form of hearing loss in OI 
(Garretsen et al. 1997). Additionally, a mild, high-frequency sensorineural hearing 
loss has been suggested as characteristic of OI (Shapiro et al. 1982b). Sensorineural 
hearing loss, including high frequency hearing loss, and anacusis has been reported in 
constant proportions independent of age (Garretsen et al. 1997). The hearing loss in OI 
is strongly age-related with an estimated annual increase of 1-1.7dB (Garretsen et al. 
1997). 
 
In the sixties, otosclerosis was suspected to be a local form of OI (Hall et al. 1961).  
However, further studies have revealed that hearing impairment in OI and otosclerosis 
are two histologically, enzymatically and etiologically distinct entities with clinical 
similarities (Altmann et al. 1967; Bretlau et al. 1969; Holdsworth et al. 1973). 
Compared with otosclerosis, hearing loss in OI has a tendency to earlier onset, more 
severe middle ear involvement, and a higher incidence of sensorineural hearing loss 
(Bergstrom 1981; Bergstrom 1977; Garretsen et al. 1997; Shapiro et al. 1982b; Shea et 
al. 1982; Shea et al. 1963; Stewart & O'Reilly 1989).  
 
Functional ossicular discontinuity, due either to stapes superstructure fracture or 
fibrous replacement or thick and fixed stapes footplate, has been suggested as the main 
etiology for the conductive hearing loss in OI (Armstrong 1984; Bergstrom 1981; 
Igarashi et al. 1982; Pedersen et al. 1979). Cochlear hair cell loss, stria vascularis 
atrophy and calcification, tectorial membrane distortion and perilymph hemorrhage, 
on the other hand, have been reported in autopsy findings, and have been suspected of 
accounting for sensorineural hearing loss (Bergstrom 1981). In addition, in 
histological studies of temporal bones, deficient ossification of the otic capsule and 
ossicles has been described (Bergstrom 1977; Igarashi et al. 1982; Pedersen et al. 
1985). In severe OI with intrauterine fractures, intracochlear hemorrhage and 
persistent cartilage in areas ossified in a normal child of the same age of six weeks 
have also been reported (Bergstrom 1977). 
 
 
2.2.4. Treatment  
 
Audiometric examinations have been recommended for the diagnosis of OI, with 
repeated studies every third year after adolescence, especially during the second to 
third decade of life (Byers 2002; Cox & Simmons 1982). As in otosclerosis, the 
hearing loss in OI may be treated with hearing aid or stapes surgery, that has become a 
safe and reasonable alternative to hearing aids in OI (Pedersen et al. 1983; Riedner et 
al. 1980; Shea & Postma 1982; Van Der Rijt et al. 2003). In addition, also cochlear 
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implantation has been reported (Huang et al. 1998). So far, to our knowledge, no 
reports of a bone-anchored hearing aid (BAHA) in OI have been published. 
 
2.2.4.1. Stapes surgery 
 
2.2.4.1.1. Surgical anatomy of middle ear in OI   
 
The typical surgical findings in the middle ear of an OI-patient with hearing loss are 
thick and fixed or obliterated footplate, thick and vascular mucosa with excessive 
bleeding tendency, and brittle atrophic crura (Armstrong 1984; Dieler et al. 1997; 
Ferekidis et al. 2000; Opheim 1968; Pedersen & Elbrond 1983; Shea & Postma 1982; 
Shea et al. 1963; Van Der Rijt & Cremers 2003). Crural fractures, closed round 
window, total bony closure of the oval window, and deficient, short ossicles are also 
reported (Albahnasawy et al. 2001; Armstrong 1984; Dieler et al. 1997; Pedersen & 
Elbrond 1983; Shea & Postma 1982; Shea et al. 1963; Van Der Rijt & Cremers 2003). 
The footplate may be mobile (Albahnasawy et al. 2001; Armstrong 1984). Compared 
with the dense, hard bone seen in otosclerosis, the footplate area in OI often presents 
with soft, granular or iceberg type bone, and the footplate may be several times normal 
thickness (Kosoy et al. 1971; Patterson et al. 1970; Pedersen & Elbrond 1983; Shea et 
al. 1963; Sooy 1960). The middle ear may also present with massive adhesions (Shea 
et al. 1963). 
 
 
2.2.4.1.2. Surgical techniques and results 
 
Despite the challenges in surgery caused by the anatomical peculiarities in the middle 
ear, the postoperative hearing results have been encouraging, albeit not as satisfactory 
as in otosclerosis (Armstrong 1984; Cremers et al. 1991; Garretsen et al. 1990; 
Glasscock et al. 1995; Palva et al. 1977; Pedersen & Elbrond 1983; Shea & Postma 
1982; Van Der Rijt & Cremers 2003). Furthermore, it has also been suggested that 
conductive hearing loss in OI can be surgically relieved with about the same level of 
predictability as in those with otosclerosis, provided that the surgeon is aware of the 
particular problems that may occur (Armstrong 1984; Cohen 1984; Dieler et al. 1997).  
Problems in surgical treatment are different from otosclerosis: the canal skin may be 
thinner and the scutum bone more brittle, stapes crura may be easily fractured, and 
troublesome bleeding may occur (Patterson & Stone 1970; Pedersen & Elbrond 1979; 
Van Der Rijt & Cremers 2003). Slight worsening of the bone conduction thresholds 
after the surgery has been reported (Garretsen & Cremers 1990; Pedersen & Elbrond 
1983). Also postoperative anacusis (PTA500-2000a more than 90 dB) has been reported 
in earlier studies in OI, as well as in otosclerosis surgery (Cremers et al. 1991; 
Garretsen & Cremers 1990; Glasscock et al. 1995; Kosoy & Maddox 1971; Palva et 
al. 1977; Patterson & Stone 1970; Van Der Rijt & Cremers 2003). 
 
Stapedotomy is today the method of choice in otosclerosis surgery (Glasscock et al. 
1995; McGee 1983). Furthermore, laser-assisted stapedotomy has been found to be 
less traumatic than conventional techniques, and it minimizes the risk of oval window 
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bleeding (McGee 1983). Laser-assisted stapedotomy might be the method of choice 
also in middle ear surgery in OI, particularly because of the risk of troublesome 
bleeding (Patterson & Stone 1970; Pedersen & Elbrond 1979). 
 
Hearing results may be better with centralized surgery (Armstrong 1984; Garretsen & 
Cremers 1990; Van Der Rijt & Cremers 2003). In general, long-term hearing results 
have been reported as satisfactory (Ferekidis et al. 2000; Garretsen & Cremers 1990; 
Pedersen & Elbrond 1979). However, progressive sensorineural hearing loss arising 
independently of the operation as a result of progression of the disease process in OI, 
appears to have a severe influence on the final hearing threshold. Out of the ten 
patients with unsuccessful surgical outcome in Garretsen´s study, eight had early 
sensorineural hearing loss prior to the surgery (Garretsen et al.1991b).  
 
2.3. Vestibular disturbances in Osteogenesis imperfecta 
 
2.3.1. Definition 
 
Dizziness is a symptom, not a disease, resulting in uncertainty of position or motion in 
space. Clinically it may be divided into four types. Type I dizziness is true vertigo, 
presenting with a definite rotational component, implying a vestibular abnormality of 
central or peripheral origin. Type II often accompanies cardiovascular abnormalitites; 
it is syncope-like and presents with a feeling of loss of consciousness. Type III occurs 
in patients lacking appropriate sensory input to maintain normal equilibrium, 
presenting with multisensory difficulties, which produce a lack of balance and 
coordination. Type IV is a light-headed sensation, diffuse and non-descript, including 
all diffuse sensations not otherwise included in types I, II and III (Paparella et al. 
1991). 
 
 
2.3.2. Prevalence and characteristics 
 
Very little is written about vertigo in OI, and the prevalence is unknown. Bronson was 
the first to mention balance problems in a patient with OI in 1917 (Bronson 1917). 
Although Gottstein, already in 1932, postulated that patients with OI often have 
balance disturbances, no studies on vertigo in OI have been published (Gottstein 
1932). Stoller presented, in 1962, a case report of a 46-year-old female with blue 
sclerae, recurrent fractures, severe episodic vertigo and gradual hearing loss resulting 
in anacusis. Right vestibular neurectomy cured the vertigo (Stoller 1962).  
 
In the literature, vertigo has mostly been reported as a symptom of basilar impression, 
a craniocervical abnormality sometimes associated with OI. Vestibulocerebellar 
symptoms, giddiness or imbalance, poor balance and gait, and cough headache in the 
occipital area with brief sensations of postural instability and syncope have been 
described. Moreover, dizziness and loss of balance while coughing, sneezing, laughing 
and bending over, as well as neck extention producing vertigo have been described as 
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symptoms of this craniocervical malformation (Elies et al. 1980; Hayes et al. 1999; 
Pozo et al. 1984; Sawin et al. 1997; Sillence 1994). Vertigo precipitated by head 
movements has been reported to be pathognomonic for basilar impression (Elies & 
Plester 1980; Hayes et al. 1999). 
 
Otosclerosis patients present with vestibular dysfunction with frequencies from 27.7 to 
57.7 %, but the etiology of sensorineural hearing loss as well as vertigo in otosclerosis 
is still unknown (Cody et al. 1978; Ghorayeb et al. 1978; Morales-Garcia 1972; 
Virolainen 1972). Particularly patients with sensorineural hearing loss due to 
labyrinthine or cochlear otosclerosis are thought to suffer from vertigo (Cody & Baker 
1978; Thomas et al. 1981). Biotoxic effects on the peripheral vestibular nerve, 
otosclerotic vascular changes due to the disease, and biochemical changes in the inner 
ear fluids have been suggested as etiological factors of vertigo in otosclerosis (Igarashi 
et al. 1982; Virolainen 1972). 
 
2.4. Basilar impression and invagination 
 
2.4.1. Definition and prevalence 
 
”Basilar impression” refers to a pathological anatomical condition where the 
uppermost cervical vertebrae intrude into the foramen magnum, producing variable 
pressure effects on the medulla and adjacent parts of the central nervous system 
(Chamberlain 1939; McGregor 1948). ”Basilar invagination” is a radiological 
designation for a status where the head is positioned abnormally inferiorly in relation 
to the uppermost cervical vertebrae, and most patients with basilar impression also fill 
the criteria of basilar invagination (Hayes et al. 1999). 
 
The prevalence of BI (basilar impression or invagination) in population studies of OI 
has been reported to be 10.5-25% (Charnas et al. 1993; Pozo et al. 1984; Sillence 
1994). 
 
 
2.4.2. General characteristics 
 
In most cases, BI is caused by congenital developmental defects in the cervico-
occipital region (McGregor 1948). In OI, it is thought to be secondary to softness of 
the skull (McGregor 1948; Pozo et al. 1984). BI has been reported to often affect 
patients with a mild to moderate type of OI (Pozo et al. 1984; Sillence 1994). Most 
patients seem to develop the symptoms in the second to fourth decades of life (Hayes 
et al. 1999). 
 
In BI, symptoms of cranial nerve involvement, constriction of the cord in the region of 
the first cervical segment, and degenerative changes in the lower cervical segments 
may appear (McGregor 1948). Pure cerebellar disturbances are rare, whereas 
headache, lower cranial nerve dysfunction, pyramidal tract signs and 
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vestibulocerebellar symptoms are reported to be common (Elies & Plester 1980; 
Hayes et al. 1999; Sawin & Menezes 1997). Vertigo precipitated by head movements 
has been reported to be pathognomonic for BI (Elies & Plester 1980; Hayes et al. 
1999). Hearing loss has also been mentioned as a symptom of basilar impression (Elies 
& Plester 1980). 
 
In most severe cases, spastic paraparesis, transient tetraparesis and acute respiratory 
failure have been reported, and a disease history from asymptomatic ventricular 
dilatation, through the foramen magnum compression syndrome, may lead to death 
from brain-stem compression (Chandy et al. 1991; Harkey et al. 1990).    
 
However, patients with BI may also be asymptomatic (Sawin & Menezes 1997). 
 
2.4.3. Treatment 
 
According to Harkey, previous surgical procedures for BI have involved suboccipital 
decompression and an upper cervical laminectomy, with operative outcomes from 
perioperative death to good functional recovery. Neurological abnormalities have 
often persisted after these operations because of the unchanged distortion of the brain 
stem. Therefore, extensive removal of the anterior bony compression by a transoral 
approach has become a recommended treatment. This has been followed by a 
posterior rigid fixation that transfers the weight of the head to the thoracic spine, in an 
effort to prevent further basilar invagination. The results of surgery have been 
relatively good, despite the difficult procedure (Harkey et al. 1990; Hayes et al. 1999).  
 
2.5. Genotype-phenotype correlation 
 
The association between clinical disease and basic molecular genetic defect, i.e. the 
phenotype and genotype in OI has been searched for, in the hope of better understanding 
the wide variation in expressivity and heterogeneity that still causes difficulties in 
clinical classification of both familial and sporadic cases (Cole 1997; Sillence 1981; 
Sillence et al. 1979b; Ward et al. 2001). The clinical variability is partly explained by 
the variety of mutations in the COL1A1 and COL1A2 genes leading to phenotypes 
ranging from mild to severe and lethal conditions (Ward et al. 2001).  In general, 
mutations reducing the amount of type I collagen synthesised by tissues lead to the 
mildest phenotypes. The wide range of phenotypes from extremely mild to lethal is 
caused by mutations altering the structure of the proachains leading to the formation of 
abnormal molecules (Byers et al. 1991; Cole 1997; Wenstrup et al. 1990). The genotype-
phenotype correlation in OI has mainly been focused on the overall severity of the 
disease, while the correlation between the mutation and hearing loss has not been 
extensively studied earlier (Byers et al. 1991; Cole 1997; Wenstrup et al. 1990). 
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3. Aims of the study 
 
The general purpose of the study was to investigate the prevalence of OI in Finland, 
the hearing loss and balance problems in this rare disorder of connective tissues and 
skeleton.  
 
The specific aims were: 
 
 
1. To study the prevalence, age of onset and type of hearing loss in children with OI. 
 
2. To study the prevalence and characteristics of hearing loss in adults with OI. 
 
3. To study the vestibulocochlear disturbances and their possible associations with 
cervicocranial secondary deformations in adults with OI. 
 
4. To evaluate the results of middle ear surgery for hearing loss in OI in Finland. 
 
5. To analyse the possible correlation between hearing loss and basic molecular 
defects. 
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4. Patients and methods 
 
4.1. Ascertainment of patients 
 
In 1995-1996, a nationwide search for OI patients in Finland was made through the 
patient register of the Department of Clinical Genetics, Helsinki University Central 
Hospital, through the membership register of the Finnish Osteogenesis imperfecta 
Association, and the HILMO care register from the Finnish university and central 
hospitals. In addition, some cases were found through family histories.  
 
Through the sources listed above, 254 Finnish OI patients found by 1996 were 
included in the present studies. The patients were approached through a questionnaire 
concerning the history of fractures, colour of sclerae, DI and hearing loss (I, II). 
During the study period, 1995-2002, an additional 45 OI patients were found. They 
were not included in the studies on hearing loss, but they were included in the 
prevalence study. By the end of the year 2002, 205 Finnish OI patients had consented 
to participate in the studies (I-V). Of these patients, 144 were adults, and 61 were 
children 16 years of age or younger at the time of the study. A clinical geneticist had 
determined the type of OI in 200 of the 205 patients using the criteria introduced by 
Sillence (Sillence et al. 1979b).  
 
The population data obtained from the Population Register Centre 
(Väestörekisterikeskus) were used to calculate the prevalence of OI in Finland. The 
point prevalence based on 299 known OI patients and the population in Finland, 5 206 
295, was calculated on December 31st 2002. 
 
 
4.2. Clinical history and confirmation of the diagnosis 
 
The diagnosis was confirmed in all sporadic cases and in most familial patients by 
clinical and genetic evaluation at the Department of Clinical Genetics, Helsinki 
University Central Hospital, and in the remaining patients through the hospital 
records, based on family and fracture history, as well as clinical and radiographic 
findings. The patients were asked about subjective and objective onset of hearing loss, 
the clinical course of hearing deficit, the use of hearing aids, presence of vestibular 
symptoms and surgical treatment. 
 
4.3. Audiometric evaluation (I-V) 
 
Altogether 183 patients with no additional ear disease and age over 4 years were 
included in the audiometric studies by the end of 2002, with 46 children aged 16 years 
or younger, and 137 adults over 16 years of age. The frequency and characteristics of 
hearing loss related to clinical OI classification were studied in the adults, as the 
hearing loss is most often known to begin in the second to third decade of life (II). As 
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the hearing loss may begin already in childhood, and no previous reports existed, the 
prevalence and characteristics of hearing loss were also studied in children (I). 
 
Pure tone audiometry was performed under standard conditions in a soundproof room 
at a local or university hospital.  Hearing measurements in some of the patients also 
included speech audiometry, tympanometry and measurement of stapedial reflexes 
(1kHz ipsi- and contralateral stimuli). In the 42 patients included in the vestibular 
study, Ilo Otodynamics Ltd, Great Britain, was used for analysis of Otoacustic 
emissions (OAE).  Auditory brainstem response (ABR) measurements in these 
patients were performed with Nicolet Viking IVD (III). 
 
The patients with no audiometric evaluation were excluded from the study, as were the 
patients with non-OI-related ear disease. Normal hearing was defined as pure tone 
average at the frequencies 500, 1000 and 2000 Hz (PTA 0.5-2kHz) equal to or better than 
15 dB HL in patients over 16 years and under 60 years of age, and equal to or better 
than 20 dB HL in patients 16 years or younger, as well as 60 years or older. 
Definitions of different types of hearing loss paralleling the definitions given by 
Shapiro et al (Shapiro et al. 1982b) and Pedersen (Pedersen 1984) were used:  
 
1.    Conductive hearing loss: average air-bone gap at the frequencies 0.5, 1 and 2 kHz 
greater than 15 dB with corresponding bone conduction threshold smaller than 15 dB. 
 
2. Sensorineural hearing loss: air conduction thresholds at the frequencies 0.5, 1 and 2 
kHz equal to or greater than 15 dB with corresponding air-bone gap smaller than 15 
dB. 
 
3. Mixed hearing loss: average air-bone gap at the frequencies 0.5, 1 and 2 kHz greater 
than 15 dB with corresponding bone conduction threshold equal to or greater than 15 
dB. 
 
The hearing age of the patients, i.e. the age at the time of audiometry, was registered 
(I-V). In patients with previous middle ear operation, the hearing age and an 
audiometry prior to the first operation were used (IV, V). Early sensorineural hearing 
loss was defined as mean bone conduction thresholds at speech frequencies of more 
than 20 dB at under 30 years of age (V). 
 
4.4. Vestibular and cephalometric evaluation (III) 
 
Because 44% of the adults in the audiometric study (II) reported vertigo, the frequency, 
characteristics and etiology of vertigo were further studied in a separate adult population 
(III). Adults (age over 16 years) living in the Turku or Helsinki region were approached 
through a questionnaire concerning the subjective and objective onset and the clinical 
course of eventual hearing loss or vestibular problems. Since BI has been suggested to 
cause vertigo, and BI has been reported to be most common in OI type IV, all Finnish 
adults with OI type IV were also contacted. Frequency, etiology, and characteristics of 
vestibular dysfunction could be studied in 42 of the contacted 73 patients. In addition to 
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a clinical examination and an X-ray of the cervicocranial region to detect eventual BI, 
electronystagmography with Hortmann's ENG equipment was performed.  In ENG, eye 
movements and caloric reactions, as well as spontaneous nystagmus were recorded, and 
directional preponderance was calculated. Abnormal findings in saccadic eye 
movements and in pursuit and optokinetic tests, indicating central lesions were 
recorded, and the ocular fixation index (OFI) was calculated. 
 
The cephalometric measurements from standardised lateral radiographs for the analysis 
of the skull base morphology are presented in III, Figure 1. A line was drawn on tracing 
paper from the most posterior-caudal point of the clivus (anterior margin of the foramen 
magnum) to the opisthion point (posterior margin of the foramen magnum). When the 
contour of the dens projected above this line, the patient was recorded as radiologically 
fulfilling the criteria of basilar impression. For the evaluation of basilar invagination, 
we used our own modifications of previously documented criteria (Chamberlain 1939; 
Hayes et al. 1999). We recorded as abnormal only the situations where the dens 
projected 10 mm or more above a line drawn from the most posterior point of the hard 
palate to the opisthion point. The selection of this criterion was based on our radiological 
survey of a large OI patient material revealing factors that strongly affect the level of 
the reference plane, that is, an abnormal position and angulation of the hard palate, as 
well as large structural variations in the posterior skull base in OI. (Waltimo et al, 
manuscript) 
 
4.5. Evaluation of ear surgery (IV) 
 
Pre- and postoperative data of 40 patients with middle ear surgery were collected, with 
a total of 62 operations performed between years 1961 and 2002. Seven patients were 
excluded from the study because of insufficient data, incomplete or revision surgery. 
The surgical and audiological data of 33 patients (43 operations) could be analysed.  
 
4.6. Molecular genetic analyses (V) 
 
The inclusion criteria for the mutation study were OI, a previous audiometric study 
and either a previously diagnosed hearing loss or age more than 35 years by 2002. The 
age limit was used because the hearing loss in OI is known to begin first in the second 
to third decade of life (Cox et al. 1982; Garretsen et al. 1997; Pedersen 1984; Quisling 
et al. 1979; Riedner et al. 1980).  
 
Of the total of 82 unrelated patients fulfilling the inclusion criteria, 54 consented to 
participate the study. 
 
 
4.6.1. Analyses of the COL1A1 and COL1A2 genes 
 
Blood samples were collected for the analysis of DNA.  Conformation sensitive gel 
electrophoresis (CSGE) and sequencing were used to scan the COL1A1 and COL1A2 
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genes for mutations in the 54 unrelated patients with OI. Genomic DNA was isolated 
from blood samples by standard procedures. All 51 exons of COL1A1 and all 52 exons 
of COL1A2 and the flanking sequences were amplified by PCR as described previously. 
(Korkko et al. 1998a) The PCR products were about 200-450 bp in size and contained 
at least 60 bp of exon flanking sequences. PCR amplifications were carried out in a 
reaction volume of 23 µl containing 40 ng of genomic DNA, 200 µM of each dNTP, 
0.25 µM of each primer, and 1 unit of Taq polymerase (AmpliTaq Gold, Applied 
Biosystems). The PCR conditions were an initial denaturation at 95°C for 10 min, 
followed by 95°C for 40 sec, 54-64°C for 40 sec, and 72°C for 40 sec for 35 cycles. To 
generate heteroduplexes for CSGE analysis the PCR products were denatured at 98°C 
for 3 min and annealed at 68°C for 30 min. The PCR products were analyzed on an 
agarose gel to check the quantity and quality of the products. Scanning of the PCR 
products was performed by CSGE as previously described with the exception that the 
gels were stained with SYBR Gold nucleic acid gel stain (Eugene, USA) instead of 
ethidium bromide (Korkko et al. 1998b). PCR products that contained heteroduplexes 
were sequenced with PCR primers by an automated instrument (ABI PRISM 377 or 
3100 Sequencers and ABI PRISM Dye Terminator Cycle Sequencing Ready Kit, 
Applied Biosystems). Prior to sequencing, the samples were treated with exonuclease I 
and shrimp alkaline phosphatase (Hanke et al. 1994; Werle et al. 1994). 
 
 
4.6.2. Genotype-phenotype correlation analysis 
 
Mutations were classified in two ways. In the first classification, mutations were divided 
into those that were found in COL1A1, and those localized in COL1A2. In the second 
classification, the mutations were divided into four subgroups. Subgroups one and two 
contained single base mutations resulting in glycine substitution in proα1(I) and 
proα2(I), respectively. The third subgroup consisted of mutations that altered consensus 
RNA splicing sequences. These mutations usually lead to exon skipping or intron 
inclusion or the use of a cryptic splice site (Pace et al. 2001a; Pace et al. 2001b). The 
fourth subgroup included nonsense and frameshift mutations, which typically lead to 
haploinsufficiency through nonsense-mediated mRNA decay. 
 
Eventual statistical dependencies of these different types of mutations and onset, 
presence, type and severity of hearing loss, as well as early sensorineural hearing loss 
or expression of hearing loss in families with several affected persons with OI were 
sought. Further, an eventual correlation of the mutation to type of OI and clinical 
features like blue sclerae, fracture rate and length was sought.  
 
4.7. Statistical analyses 
  
In studies II, III and V, statistical analyses of group comparisons were carried out with 
the two sample t-test. Bivariate dependencies were performed using cross-tabulations 
(contingency tables) with related chi-square statistics and class-wise relative 
frequencies.  The chi-squared statistic indicates the existence of a possible statistical 
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dependency between the categorical variables, while percentage distributions in 
classes of one of the variables enable us to identify the fashion in which the variables 
are dependent on each other. In the cases of 2 by 2 cross-tabulations, and where the 
sample size remained small, we utilized the so-called Fisher's exact test for testing the 
independencies. The advantage of this procedure is that it does not rely on the large 
sample theory like the usual chi-square analysis, and hence should be more powerful 
in detecting possible dependencies. 
 
In study IV, statistical analyses of the postoperative changes in hearing were carried 
out with the paired t-tests.  The usual two-sample t-test and the chi-square test were 
utilized in the analyses of operative results, on one hand between university and 
central hospitals, and on the other hand, between single surgeon and multiple 
surgeons. F-test was used in investigation of the homogeneity (equality of variances) 
of the pre- and post-operative hearing results. 
 
4.8. Ethics 
 
The Joint Ethical Committee of Turku and Helsinki University Central Hospital 
approved the studies. Permission to acquire the patient data was granted by the 
Ministry of Health and Social Affairs. 
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5. Results 
 
5.1. Osteogenesis imperfecta in Finland 
 
5.1.1. Epidemiology 
 
By the end of 2002, 299 living Finnish patients with confirmed diagnosis of OI were 
ascertained. The prevalence of the known cases of OI in Finland on December 31st, 
therefore, is 5.74/100 000.  
 
5.1.2. General characteristics and classification 
 
The mean age of the 299 Finnish patients was 35 years at the end of 2002. (SD 20.6 
years, range 1-94 years) Of the 166 women and 133 men, 61 were children 16 years of 
age or younger. Of the 299 patients, 105 had sporadic type of OI, while 194 were 
familial cases representing 60 different families. Four of the families consisted of 
seven patients with OI, one family of six patients, four families of five patients, nine 
families of four patients, and 42 families of three or fewer patients with OI.  
 
A clinical geneticist classified 254 patients. OI type I was most common, 78.4%. The 
type of OI among the 299 patients is presented in Figure 6.  
 
 
Figure 6. Type of OI  in the 299 Finnish patients. 
 
Altogether, 205 patients had participated in the nationwide study on hearing in OI by 
the end of 2002. By the time of the study, the mean age of 118 women and 87 men 
was 32.0 years (SD 20.0 years, range 1-81 years), and 61 of the 205 patients were 
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children aged 16 years or younger. Sex and age distributions and the classification of 
the patients are presented in Table 2. Of the patients, 133 patients had familial type of 
OI, 178 had blue sclerae, and 81 patients reported DI. The number of fractures in the 
205 patients is presented in Figure 7. Of the 205 patients included in this nationwide 
study, 200 were alive at the end of 2002. 
 
Table 2. Sex and age distribution of the 205 classified Finnish OI patients included in the 
nationwide study. 
 
  
Unclassified 
 
I 
 
III 
 
III/IV 
 
IV 
 
V 
Cole- 
Carpenter 
 
Total 
Male 2 61 4 1 16 1 0 88 
Female 3 82 6 3 25 0 1 116 
Mean age 
(years) 
33,4 33,7 25,6 25,5 28,7 43 12 32 
SD 16,24 21,3 15,4 25,2 15,9   20,1 
Range 12-55 1-81 6-49 1-58 5-65   1-81 
Total 
number of 
pts 
5 143 10 4 41 1 1 205 
 
 
Figure 7. The number of fractures in the 205 Finnish OI patients included in the study. Four 
patients had no fractures. The number of fractures was unknown in 6 patients. 
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5.2. Hearing loss (I, II) 
 
5.2.1. Patients, prevalence and general characteristics 
 
Of the 183 patients with audiometry, 46 were children aged 16 years or younger, and 
137 were adults. OI-related hearing loss in at least one ear was found in 82 of all the 
patients (44.8%), including one bilaterally operated patient with normal postoperative 
hearing. Hearing loss was bilateral in 72 of the 82 patients with hearing loss (87.8%). 
Two patients had unilateral anacusis caused by trauma. One of them also had OI-
related hearing loss, while the other patient had normal hearing unilaterally. 
 
The mean age at the onset of hearing loss according to patient history or audiometry 
was 28 years (SD 15 years, range 1-81 years). The prevalence of hearing loss 
increased with increasing age. The proportion of hearing loss in different age 
categories is presented in Table 3. Figure 8 presents the hearing pattern in the 366 ears 
with audiometry. Mixed hearing loss was the most common type of hearing loss in 
both operated and non-operated patients. Table 4 presents the type of hearing loss in 
the 183 patients with audiometry, classified according to Sillence.  
 
Since hearing measurements in only a part of the patients included speech audiometry, 
tympanometry and measurement of the stapedial reflex (1kHz ipsi- and contralateral 
stimuli), no analysis of these measurements was performed. 
 
Table 3. The proportion of hearing loss in different age categories in the 183 patients with 
audiometry      * Congenital / early sensorineural hearing loss          
** Including one patient with unilateral traumatic deafness                 
*** Including one patient with normal postoperative hearing 
 
  
<10 
years 
 
10-19 
years 
 
20-29 
years 
 
30-39 
years 
 
40-49 
years 
 
50-59 
years 
 
60-69 
years 
 
>70 
years 
 
Total 
Normal 
hearing 
19 29 15** 19 9 7 3 0 101 
 
Hearing 
loss 
1* 
(5%) 
4 
(12.1%) 
12 
(44.4%) 
19 
(50%) 
15** 
(62.5%) 
13 
(65%) 
8  
(72.7%) 
10  
(100%) 
82 
Total 
number  
of pts 
20 33 27 38 24 20 11 10 183 
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Figure 8.  Hearing pattern in the 366 ears of the 183 patients, with hearing pattern of the 
patients with previous ear surgery presented separately. For definition of various types of 
hearing loss, see page 28. 
 
Table 4. The type of hearing loss in the 366 ears of the classified 183 patients (Glorieux et al. 
2000; Glorieux et al. 2002; Hall 2002; Sillence 1981). Operated patients are presented 
separately. For definition of various types of hearing loss, see page 28. 
  
I 
 
III 
 
III/IV 
 
IV 
 
V 
Cole- 
Carpenter 
 
Unclassified 
 
Total 
Normal 140 13 2 48 2 2 4 211 
Conductive 6 1 1 8 0 0 0 16 
Mixed 29 4 0 4 0 0 1 38 
Sensorineural 30 0 2 2 0 0 1 35 
Anacusis 9 0 0 1 0 0 0 10 
Undefinied 4 1 0 0 0 0 0 5 
Excluded 1 0 0 1 0 0 0 2 
Operated 37 1 1 10 0 0 0 49 
Total 256 20 6 74 2 2 6 366 
 
5.2.2. Hearing loss in children with OI (I) 
Hearing loss was found in three of the 46 children with audiometry. An 11-year-old 
girl and a 15-year-old boy with severe sporadic type IVB OI had earlier undiagnosed 
conductive hearing loss, with PTA 0.5-2kHz 35/40 dB HL and 27/18 dB HL (right/left 
ear), respectively (I, Fig. 1 and 2). The third patient, a 7-year-old girl with familial OI 
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type I had either congenital or severe progressive sensorineural deafness observed at 
the age of 8 months (I, Fig. 3). According to the parents, the girl behaved like a 
normal-hearing child up to the age of six months. She had been treated with weight-
adapted doses of Tobramycin during four operations for bilateral congenital hip 
luxation. OI was diagnosed when the left femur was fractured peroperatively at the 
age of 9 months. Seven relatives had blue sclerae but no bone fractures or hearing 
loss, and, therefore, no diagnosis of OI. Tympanic membranes were of normal 
appearance, and the PTA 0.5-2kHz was 97/103dB HL.  
 
5.2.3. Hearing loss in adults with OI (II) 
 
Of the 137 adults with audiometry, 57.7% had hearing loss. Subjective sensation of 
hearing ability was misjudged by 18.2%, that is, 17% of the patients with normal 
hearing sensed hearing loss, and 12.7% of the patients with hearing loss did not 
recognize it. Hearing loss was bilateral in most patients. Mixed and sensorineural 
hearing loss occurred in all age groups, while conductive hearing loss was 
predominantly found in younger patients (II, Fig. 4). No clear correlation was found 
between clinical type of OI and presence of hearing loss. The patients with OI type IV, 
however, tended to have less hearing loss than the patients with OI type I and III 
(Fisher p=0.054) (II, Fig. 6). On the other hand, patients with hearing loss tended to 
have fewer fractures than patients with normal hearing (Fisher p 0.054). No 
correlation was found between severity, occurrence, or type of hearing loss and 
clinical features of OI such as blue sclerae, DI, vertigo, or whether the OI was 
sporadic or familial (II, Fig. 7 and 8). 
 
Four adults had severe deafness (PTA500-2000 > 90 dB) not related to surgery. A 49-
year-old woman with non-familial OI type I developed rapidly progressing hearing 
loss resulting in anacusis at the age of 22 years (II, Fig. 9). A 47-year-old man with 
blue sclerae and DI but no fractures, had anacusis of the right ear reported at the age of 
seven years. In addition, progressive hearing loss resulted in bilateral anacusis in two 
patients with mild OI type I: at the age of 71 years in a woman, and at the age of 73 
years, in a man. In addition, eight non-operated patients had sensorineural hearing loss 
before the age of 40 years. Seven of these patients had OI type I, and one patient with 
blue sclerae and DI was not classified. Indicative statistical dependency between 
inner-ear-related hearing loss and OI type I was found (p 0.069). 
 
   
5.3. Vestibular dysfunction and basilar impression (III) 
 
5.3.1. Prevalence and general characteristics 
 
Of the 42 adults consenting to participate in the study 52.4% reported vertigo. The 
mean age of the 12 men and 30 women was 39.1 years (SD 11.4, range 19-69 years). 
Twenty-one patients had OI type I, 5 had OI type III and 15 had OI type IV (III, Table 
II). Nine patients were bound to a wheelchair, while 25 patients walked without aid.  
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5.3.2. Audiological findings 
 
At audiometry, 59.5% had hearing loss that was mostly bilateral. Hearing loss with a 
sensorineural component was present in all but two patients who had conductive 
hearing loss (III, Fig.2). ABR was pathological in 52% of the 25 patients with hearing 
loss, with a clear statistical association (p=0.0072). ABR pathology, such as abnormal 
fifth wave latency or side difference of the fifth wave latency, was not associated with 
vertigo, presence of BI, or with deviant ENG results. 
 
5.3.3. Neurological symptoms and findings 
 
Of the 42 patients, light-headedness was reported by 59.5%. Thirteen patients had 
sensory defects of the skin, and five of these patients also presented with BI. None of 
the 42 patients had head-shaking nystagmus. Two patients had spontaneous nystagmus 
with Frenzel´s glasses, but not at ENG. Both patients had vertigo, hearing loss and 
tinnitus, but normal skull base.  
 
Subjective symptoms possibly deriving from the central nervous system were reported 
by 11 patients: two patients had attacks of syncope, one of them also presenting with 
BI. Seven patients presented with visual blurring or diplopia, three of them also 
suffering from BI. Three patients reported attacks of dysartria, and three patients 
suffered from sensory defects of the skin of the face, with one patient in each group 
also presenting with BI. 
 
5.3.4. Vestibular symptoms and findings 
 
Vertigo mostly presented as short episodes of floating or rotational sensation, often 
related to rapid head movements or altered position. Head movements or altered 
position caused vertigo in 16 of the 22 patients with vertigo (72.7%).  
 
Patients with hearing impairment had more vertigo (62.5%) than patients with normal 
hearing (43.7%), but the difference was not statistically significant (p=0.1). The type 
of hearing loss was not associated with vertigo. The operated patients did not differ 
significantly from the non-operated patients regarding frequency, duration, severity or 
type of vertigo. 
 
5.3.5. Electronystagmographic findings 
 
A generally mild ENG pathology was found in 14 patients (33.3%) (III, Table IV). No 
correlation between deviant ENG results and vertigo was found. Patients with more 
severe hearing loss also had more deviant findings at ENG (p=0.049). ENG pathology 
also tended to be more common in patients with sensorineural or mixed type of 
hearing loss as compared with patients with normal hearing or conductive hearing loss 
(p=0.0768). Patients with previous stapedotomy had significantly more ENG 
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pathology indicating a peripheral vestibular lesion. No correlation between BI and 
pathology at ENG was found, although a central-type ENG abnormality seemed to be 
more common in patients with BI (p=0.118).  
 
5.3.6. Radiological findings 
 
Nine patients presented with radiologically defined BI (III, Table III). The mean age 
of these patients was 38.8 years (SD 15.1, range 20-69 years). Patients with BI had 
significantly more subjective symptoms deriving from the central nervous system than 
patients with normal skull base (p=0.036). No correlation between the presence or 
absence of BI and the type of OI was found, nor between the type of hearing loss and 
BI. The frequency of vertigo related to altered position or head movements was not 
significantly more common in patients with BI as compared with other patients, and 
the characteristics of vertigo were similar in both patient groups.  
 
 
5.4. Results of stapes surgery (IV) 
 
Surgical and audiological data of 43 middle ear operations performed from 1961 to 
2001 were analysed. The mean age of the 33 patients at the onset of subjective hearing 
loss was 20.8 years (SD 6.1, range 10-35 years), and by the time of the surgery 30.1 
years (SD 9.4, range 15-53 years). In 13 of the 43 operations the diagnosis of OI was 
not made preoperatively, although 12 of these patients had blue sclerae, DI was 
present in five patients, and all but one patient had had fractures. OI type I was most 
common in the operated patients (IV, Figure 1). 
 
5.4.1. Surgical methods and anatomy of the middle ear  
 
Of the operations, 75% were stapedotomies (19 ears) or stapedectomies (13 ears) (IV, 
Table 3). The most frequent surgical findings in the middle ear in the 43 operations 
were thick, fixated or obliterated footplate, thick and vascular mucosa with excessive 
bleeding tendency and elastic, fractured or atrophic stapes crura. Fibrosis was also 
common (IV, Table 4). 
 
5.4.2. Outcome and audiometric results 
 
The pre- and postoperative hearing level in the operated 43 ears is presented in IV, 
Fig. 2 A-C. These operations were performed by 20 different surgeons in five 
university hospitals and five central hospitals. One surgeon operated on three ears, 
four surgeons operated on two ears each, while fifteen surgeons operated on one ear 
each. In addition, one surgeon performed sixteen operations.  
 
In spite of similar preoperative PTA500-2000 in university and central hospitals, a 
statistically significant improvement in PTA500-2000 was found in university hospitals 
compared with central hospitals (p 0.005). In addition, an overall deterioration in the 
Results 
 45 
mean bone conduction thresholds at speech frequencies from 500 to 2000 Hz was 
found (from 15.7 to 18.6 dB) in the central hospital group, while an overall 
improvement was noticed (from 21.0/16.2 dB) in the university group. Furthermore, 
the results of the 16 operations performed by a single surgeon in the university group 
were more homogenous, and the hearing gain was better, although the difference was 
not statistically significant.  
 
One patient presented with anacusis at the first postoperative follow-up (PTA500-2000 
100 dB HL; patient number 3 in IV, Fig. 2). This 23-year-old woman with severe form 
of OI type III/IV had a preoperative bilateral hearing loss (PTA500-2000 23.3/63.3dB HL 
dx/sin). In the operated left ear, the facial nerve was reported to be nude, and the 
thread-like long process of the incus was in the supine position, forcing the prosthesis 
to be placed in the malleus instead of incus.  
  
 
5.5. Molecular pathology and genotype-phenotype analysis (V)  
 
Mutations either in COL1A1 or COL1A2 were found in 49 of the 54 patients (V, 
Table 2). Thirty-two of the 49 patients had familial OI and 16 had sporadic disease.  
One patient could not be classified as familial or sporadic, since the family members 
could not be examined. These 45 patients represent the molecular genetic background 
of 123 of the 299 Finnish OI patients (41.1%) known by the year 2003. The mean age 
of the 19 men and 30 women at the time of the audiometry was 36.4 years (SD 11.1 
years, range 12-59 years). Most of the patients had OI type I (V, Fig. 1). Forty had 
blue sclerae (81.6 %), and all but one suffered fractures.  
 
 
5.5.1. Molecular genetic findings 
 
A total of 47 different mutations were identified in 49 patients, as an identical 
mutation was present in two non-related patients (V, Table 2). CSGE analysis and 
complete sequencing of the genes did not detect mutations in five patients. Thirty-
eight of the mutations were in COL1A1 and eleven in COL1A2. Sixteen patients had a 
mutation resulting in glycine substitutions in COL1A1 or COL1A2. Six glycine 
mutations were in COL1A1, and ten in COL1A2. Mutations in the consensus RNA 
splicing sequences were found in sixteen patients. One OI type III patient with a two 
nucleotide deletion in exon 33/34 of COL1A1 (c.2268-2269delTC) was included in 
this group.  
 
Four nonsense mutations and thirteen frameshift mutations, predicted to result in 
nonsense-mediated mRNA decay, were found in COL1A1. Two unrelated patients had 
the same c.299insC mutation. Also a nonsense mutation, R848X, appeared in two 
unrelated patients.  
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5.5.2. Audiometric findings 
 
Of the 49 patients with a mutation in either COL1A1 or COL1A2, 32 had hearing loss 
(65.3 %) (V, Table 3). The mean age at the onset of hearing loss was 23.9 years (SD 
8.0, range 12-45 years). Hearing loss was found in all OI types (V, Fig. 2).  
 
According to the audiometric studies, 15 of the 32 patients with hearing loss had early 
sensorineural hearing loss, i.e. bone conduction thresholds at speech frequencies 500-
2000 Hz were 20 dB HL or more before the age of thirty years in a previous 
audiometry. One patient had anacusis. The first audiometry in this woman with OI 
type I was performed when she was 20 years of age. She was found to have a 
progressive hearing loss of mixed type. Rapid progression of the hearing loss resulted 
in total anacusis at the age of 22 years (V, Table 2, patient number 17).  
 
The pattern of familial hearing loss could be studied in 14 cases. No correlation was 
found between the OI type and expression of hearing loss in families.  
 
 
5.5.3. Genotype-phenotype correlation 
 
The mutation and clinical data of the 49 patients are presented in V, Table 2. The 
mutated genes correlated with the OI types. COL1A1 mutations were more frequent in 
OI types I and III, and COL1A2 mutations were more frequent in OI type IV 
(p=0.00086). 
 
The association between the four different mutation subgroups and clinical OI types 
was statistically significant (p=0.0010), predominantly due to the association of null 
allele mutations with OI type I and partially due to the association of glycine 
substitutions in proα2(I) with OI type IV (V, Table 4). Patients with COL1A1 
mutations more often had blue sclerae (p=0.0327), and they tended to be taller 
(p=0.0443, t-test) than the patients with COL1A2 mutations.  
 
Mutations in COL1A1 were as likely to cause hearing loss as COL1A2 mutations 
(p=0.725). The presence of hearing loss did neither correlate with the different 
mutation types (p=0.452), nor did the type or severity of the hearing loss correlate 
with the mutated genes or different mutation types. Early sensorineural hearing loss or 
expression of hearing loss in the families did not correlate with the mutation types. 
 
5.5.4. Patients without detectable mutations in COL1A1 or COL1A2 
 
In five patients, no mutation was detected by CSGE or sequencing of all exons in 
COL1A1 or COL1A2.  
 
Two patients had sporadic OI type I and moderate bone fragility. A 69-year-old 
woman (height 153 cm) had normal hearing, and a 41-year-old woman (height 161 
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cm) had conductive/mixed hearing loss (right/left ear). A 55-year-old woman (height 
163 cm) with familial OI type I from a family with twelve affected members in three 
generations had a moderate fracture rate and mixed hearing loss bilaterally. A 41-year-
old, 157 cm tall woman with sporadic OI type IV and moderate bone fragility had 
white sclerae and normal hearing. A 48-year old, 130 cm tall man with sporadic OI 
type V had moderate bone fragility and normal hearing.  
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6. Discussion 
 
6.1. General discussion 
 
This is the first study on OI in Finland, covering all known patients and evaluating 
hearing problems as a symptom of OI. This is also the first whole population study in 
which molecular genetic analysis has been applied in OI. 
 
In earlier population studies in Sweden, Norway and Denmark, prevalence figures 
between 3.3/100 000 and 5/100 000 have been found (Heiberg 1983; Pedersen 1983; 
Smårs 1961). During this study, a total of 299 cases of OI from a population of 5.2 
million was found, corresponding to a prevalence of 5.74/100 000. The true 
prevalence of OI in Finland is most probably greater, and patients with severe forms 
compared with mild forms may be over-represented, as the mild forms may still today 
remain undiagnosed.  
 
Prior to the present study, six population studies on hearing loss including all types of 
patients with OI have been published. In these studies, hearing loss has been found in 
22.6-58% of the OI patients (Paterson et al. 2001; Pedersen 1983; Seedorff 1949; 
Sillence et al. 1979; Smårs 1961; Stewart et al. 1989). Bilateral, progressive hearing 
loss often starts in the second to third decade of life, it is predominantly conductive at 
onset, and later mixed or sensorineural (Bergstrom 1977; Cox et al. 1982; Garretsen et 
al. 1997; Pedersen 1984; Quisling et al. 1979; Riedner et al. 1980). Hearing loss is 
reported to be most common in OI type I, and it is thought to be less common in OI 
type IV(Garretsen et al. 1997; Garretsen et al. 1991; Sillence 1981; Sillence 1988; 
Stewart & O'Reilly 1989). Comparison of the studies, however, is difficult as the 
definition of hearing loss may be missing or varies greatly, and the study subjects may 
be selected (Garretsen et al. 1997; Garretsen & Cremers 1991; Paterson et al. 2001; 
Pedersen 1984; Sillence 1981; Sillence 1988). 
 
Vertigo in OI patients has not, to the best of our knowledge, been studied earlier, 
although hearing loss is one of the major symptoms in OI, and vertigo is frequently 
associated with otosclerosis in which the hearing loss clinically resembles that in OI 
(Virolainen 1972). In otosclerosis, the prevalence of vertigo has been reported to 
increase with an increasing sensorineural component in the hearing pattern (Cody et 
al. 1978; Thomas et al. 1981). Vertigo, as well as sensorineural hearing loss, are also 
common symptoms in BI, which is reported in up to 25% of OI adults (Elies et al. 
1980; Sawin et al. 1997; Sillence 1994). BI has been reported to be most prevalent in 
OI type IVB, and in more severely affected individuals with OI (Charnas et al. 1993; 
Elies & Plester 1980; Sawin & Menezes 1997; Sillence 1994).  
 
Although there are clinical similarities with otosclerosis, hearing loss in OI is a 
distinct entity with earlier onset, more severe middle ear involvement, and higher 
incidence of sensorineural hearing loss (Bretlau et al. 1969; Garretsen et al. 1997; 
Holdsworth et al. 1973; Shapiro et al. 1982; Shea et al. 1963; Stewart & O'Reilly 
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1989). The typical surgical findings in the middle ear of an OI-patient with hearing 
loss are thick and fixated or obliterated footplate, thick and vascular mucosa with 
excessive bleeding tendency, and brittle atrophic stapes crura. Crural fractures, closed 
round window, fragile incus, and deficient, short ossicles have also been reported 
(Armstrong 1984; Pedersen et al. 1983; Shea et al. 1982; Van Der Rijt & Cremers 
2003). Compared with the dense, hard bone seen in otosclerosis, the footplate area in 
OI often presents with soft, granular or iceberg type bone (Kosoy et al. 1971; 
Patterson et al. 1970; Pedersen & Elbrond 1983; Sooy 1960). The postoperative 
hearing results in OI surgery have been encouraging, albeit not as satisfactory as in 
otosclerosis (Armstrong 1984; Cremers et al. 1991; Garretsen et al. 1990; Glasscock et 
al. 1995; Palva et al. 1977; Pedersen & Elbrond 1983; Shea & Postma 1982; Van Der 
Rijt & Cremers 2003). 
 
The genotype-phenotype correlation in OI has mainly been focused on the clinical 
overall severity of the disease. Mutations reducing the amount of type I collagen are 
reported to produce the mildest phenotypes, while mutations altering the structure of 
the proa chains produce a wide range of phenotypes (Byers et al. 1991; Cole 1997; 
Wenstrup et al. 1990). The correlation between the mutation and hearing loss has not 
been extensively studied earlier. 
 
 
6.2. Hearing loss in children (I) 
 
The onset of hearing loss in OI most often coincides closely with the time of life when 
the frequency of fractures is decreasing in the late second decade of life (Bergstrom 
1977; Cox & Simmons 1982; Garretsen et al. 1997; Pedersen 1984; Riedner et al. 
1980). Although not emphasized in literature, hearing loss in OI may begin already in 
childhood (Cox & Simmons 1982; Pedersen 1984; Stewart & O'Reilly 1989; 
Verstreken et al. 1996). Mostly, conductive type of hearing loss has been reported in 
children (Cox & Simmons 1982; Garretsen et al. 1997; Pedersen 1984). Pedersen 
(1984) reported conductive hearing loss in 22% of the children in the age group 4-9 
years, and in 28 % in the age group 10-19 years (Pedersen 1984). However, hearing 
loss was explained by secretory otitis media in four of the five children in the younger 
age group (Pedersen 1984). In a recent Australian study, middle ear effusion was also 
found to be a main reason for conductive hearing loss in children with OI (Imani et al. 
2003). Therefore, tympanometry should be included in the diagnosing of hearing loss 
in children with OI.  
 
Garretsen´s study (1997) on type I OI patients in the Netherlands revealed the highest 
frequency of hearing loss among children so far: 31% of the children 4-9 years of age, 
and 62% of the children 10-19 years of age. The patients, however, were selected for 
ear surgery or volunteered for the study because of their hearing loss (Garretsen et al. 
1997). 
  
In our study on 46 Finnish children with audiometry, prevalence of hearing loss in the 
youngest age group studied was lower than in previous studies with audiometry (Table 
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5) (Garretsen & Cremers 1991; Pedersen 1984). This is most probably caused by the 
inclusion of children with secretory otitis media in previous studies, or the selection of 
the patients (Garretsen & Cremers 1991; Pedersen 1984). Of the 46 children between 
4 and 16 years of age, only two children with sporadic OI type IV had progressive 
hearing loss of conductive type clearly related to OI (4.4%). In addition, a girl with 
familial OI type I had anacusis diagnosed during the first year of life. An etiology 
other than OI was suspected. After a OI type I woman presented with a rapid, 
progressive hearing loss resulting in total anacusis at the age of 22 years (II), the still 
unanswered question of the possibility of OI connected anacusis in these two patients 
arouse. Stewart reported a child in the age group 10-19 years with a flat sensorineural 
hearing loss of 30 dB HL in one ear and 60 dB HL in the other, with no other 
explanation than OI (Stewart & O'Reilly 1989).  
 
This study indicates that clinically significant hearing loss in children under 16 years 
of age with OI is less frequent than suggested by previous studies. The high 
prevalence of hearing loss in previous studies may be explained by the small or 
selected study materials, and by secretory otits media, as well as by the different 
criteria used for the hearing loss (Garretsen et al. 1997; Pedersen 1984). In addition, 
the age range in our study was between 4 and 16 years of age, and not 19 years, as in 
previous studies (Table 5).  
 
No audiometry was performed in 15 of the 61 children included in the population 
study. As almost 20% of the adults were found to misjudge their hearing ability (II), 
these children may not automatically be considered as normal hearing. Early detection 
and treatment of hearing loss is of utmost importance to avoid additional disability 
that aggravates the physical handicap. Therefore, audiometry is recommended in a 
child with OI if a hearing deficit is suspected, and for an asymptomatic patient a 
baseline study at the age of 10 years with repeated audiograms every three years is 
recommended.   
 
6.3. Hearing loss in adults (II) 
More than 50% of adults with OI are reported to have hearing loss (Paterson et al. 
2001; Pedersen 1984; Sillence et al. 1979; Stewart & O'Reilly 1989). Our study 
supports this finding, as 57.7% of the 137 adults with audiometry had hearing loss 
(Table 5). Mixed hearing loss was the most frequent type of hearing loss. Conductive 
hearing loss was mostly observed in younger patients, while sensorineural and mixed 
type of hearing loss was seen in all age groups, as reported in earlier studies  
(Bergstrom 1977; Cox & Simmons 1982; Garretsen et al. 1997; Pedersen 1984; 
Quisling et al. 1979; Riedner et al. 1980).  
 
Hearing loss has been suggested to be more common in OI type I than in OI type IV 
(Paterson et al. 2001; Sillence et al. 1979). In Australia, 35% of OI type I patients of 
all ages had hearing loss. No hearing loss was found in OI type IV (Sillence et al. 
1979). In a Scottish study about 30% of patients with OI type IA, IB and IVB reported 
hearing loss at the age of 30 years, while the proportion for OI type IVA was 9% 
(Paterson et al. 2001).  
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Table 5. Hearing loss in different age categories in studies on hearing loss in Osteogenesis 
imperfecta. 
Authors 
Number 
of pts Patients 
Definition 
of hearing 
loss Audiometry 
Hearing 
loss  
all pts  
% 
4-9 
years 
10-19 
years 
20-29 
years 
30-39 
years 
40-49 
years 
50-59 
years 
>60 
years 
Pedersen 
1984 173 population yes* 
yes + 
portable 
88/173 
51% 
5/23 
22% 
10/36 
28% 
18/31 
58% 
15/29 
52% 
12/21 
57% 
8/12 
67% 
20/21 
95% 
Stewart and 
O´Reilly 
1989 53 population yes* 
yes + 
portable 
29/53 
50% 0 
2/13 
15% 
6/14 
43% 
5/7 
71% 
11/12 
92% 
7/7 
100% 0 
Garretsen 
and 
Cremers 
1991 70 OI type I yes* yes   
30/70 
43% 
2/18 
11% 
13/21 
62% 
6/13 
46% 
1/8 
13% 
2/3 
67% 
3/4 
75% 
3/3 
100% 
Paterson 
et al 
2001 1394 population no no 
317/1394 
23% 
20/466 
4% ? ? ? ? ? ? 
This study 
2003 183 population yes* yes 
82/183 
45% 
1/20 
5% 
4/33 
12% 
12/27 
44% 
19/38 
50% 
15/24 
63% 
13/20 
65% 
18/21 
86% 
 
* Definition of hearing loss varies 
 
Although no clear statistical dependency was found between the clinical type of OI 
and presence of hearing loss in our Finnish study, the patients with OI type IV may 
have less hearing loss than the patients with OI types I and III (Fisher p=0.054). In OI 
type III, the two previous studies on hearing loss have presented conflicting results 
(Paterson et al. 2001; Sillence et al. 1979). In our study, four of the five type III 
patients had hearing loss, supporting Paterson´s finding of hearing loss also being 
common in OI type III (Paterson et al. 2001). The type of hearing loss also seemed to 
be slightly different between types I and IV OI, with inner-ear-related hearing loss 
occurring more often in OI type I (F-test p 0.069). Compared with otosclerosis, a 
higher incidence of sensorineural hearing loss has been reported in OI (Bergstrom 
1977; Holdsworth et al. 1973; Patterson et al. 1970; Shea et al. 1982; Stewart et al. 
1989). In our study, sensorineural hearing loss was also found in the youngest age 
groups, indicating the existence of a group of OI patients with a predominantly 
sensorineural pattern at the onset of the hearing loss. This early sensorineural hearing 
loss was found only in patients with OI type I, and the only patient with rapidly 
progressing hearing loss resulting in anacusis within 8 years at the age of 22 years also 
had OI type I. However, in the molecular genetic study with retrospective evaluation 
of early sensorineural hearing loss as one of the characteristics of hearing loss, also 
patients with other types of OI than OI type I were found to have early sensorineural 
hearing loss (V, Table 3). In earlier studies, anacusis is reported mostly in older age 
groups, although sensorineural hearing loss in early age has also been reported 
(Pedersen 1984; Stewart & O'Reilly 1989). The etiology of early sensorineural hearing 
loss in OI remains unresolved, and further studies should be carried out. 
 
The misleading subjective assessment of hearing ability found in our study 
emphasizes the importance of regular audiometric studies in patients with OI, as 
almost 20% of adults misjudged their hearing ability.  
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6.4. Vestibular dysfunction (III) 
 
The first study on vestibular dysfunction in OI patients is presented, with 22 of the 42 
adults reporting vertigo (52.4%). Vertigo precipitated by head movements is reported 
as one of the principal neurological symptoms of BI of unspecified etiology, and it has 
also been reported in otosclerosis (Elies et al. 1980; Sawin et al. 1997; Thomas et al. 
1981; Tucker 1979). Also in our study, head movements or altered position was a 
common trigger, provoking balance problems in 72.7% of the patients with vertigo.    
 
In otosclerosis, the prevalence of vertigo has been reported to increase with an 
increasing sensorineural component in the hearing pattern (Cody et al. 1978; Thomas 
& Cody 1981). Sensorineural hearing loss and vertigo were not correlated in our 
study, but vertigo tended to be more frequent in patients with hearing loss than in 
patients with normal hearing. 
 
Vertigo was not correlated with deviant ENG results, but as in earlier reports on 
otosclerotic ears with cochlear involvement as compared with ears with conductive 
hearing loss, we also found a tendency toward more ENG pathology in the OI patients 
with sensorineural or mixed-type hearing loss than in those with conductive hearing 
loss or normal hearing (p=0.0768) (Cody & Baker 1978; Morales-Garcia 1972) (III, 
Table IV). This implies extensive damage to the inner ear.  
 
Nine patients in our study presented with BI (IV, Table III). Sensorineural hearing loss 
has previously been reported in BI, but no association between BI and presence or 
type of hearing impairment could be found in our study (Sawin & Menezes 1997). 
Although BI has been reported to be most prevalent in OI type IVB, no correlation 
between the type of OI and presence of BI was found in our study (Sillence 1994). BI 
has also been suggested to occur in more severely affected individuals with OI, but in 
our study, no correlation between BI and severity of OI was found (Charnas et al. 
1993). 
 
Our study confirms that vertigo, in addition to hearing loss, is common in patients 
with OI. As in otosclerosis, the true etiology for sensorineural hearing loss, as well as 
for vertigo in OI still remains unknown. Both the fact that the patients with hearing 
loss tended to have more vertigo, and the co-existence of sensorineural hearing loss 
and deviant vestibular findings at ENG indicate damage to the inner ear as the main 
reason for vertigo in these OI patients. A pathology similar to otosclerotic foci in 
contact with the pars superior of the vestibule or the superior vestibule nerve, as well 
as otosclerotic vascular changes due to the disease or to biochemical changes in the 
inner ear fluids are possible (Ghorayeb et al. 1978; Virolainen 1972). Vertigo in OI 
patients might also be partly explained by BI. Still, some OI patients without hearing 
loss or basilar impression also suffer from vertigo clinically indistinguishable from the 
type of vertigo seen in patients with hearing loss or BI. Therefore, patients with OI 
should be informed about the frequency of vertigo in OI, not only as a symptom of BI, 
a feared complication of OI.  
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6.5. Stapes surgery (IV) 
 
Despite the anatomical challenges, satisfying to excellent results of stapes surgery in 
OI have been presented in former studies (Armstrong 1984; Garretsen et al. 1990; 
Kosoy et al. 1971; Pedersen et al. 1983; Shea & Postma 1982; Van Der Rijt & 
Cremers 2003). The outcome of stapes surgery in Finnish patients with OI was 
evaluated in a study with 43 ears of 33 OI patients operated in Finland between 1961 
and 2002. Thirty-six of the operations were performed in university hospitals and 
seven in central hospitals. Like in previous studies, our study revealed the typical 
surgical findings in the middle ear to be thick and fixated or obliterated footplate, 
thick and vascular mucosa with excessive bleeding tendency, and elastic, fractured or 
atrophic stapes crura (Armstrong 1984; Pedersen & Elbrond 1983; Shea & Postma 
1982; Van Der Rijt & Cremers 2003). 
 
In our study, the surgically achieved hearing gain was poorer than in former studies 
(Armstrong 1984; Garretsen & Cremers 1990; Kosoy & Maddox 1971; Pedersen & 
Elbrond 1983; Shea & Postma 1982). However, it was better in university hospitals 
than in central hospitals, and after surgery performed by a single surgeon in a 
university hospital, the results were comparable with earlier studies. In addition, the 
mean bone conduction thresholds were unchanged as a result of the operation in 
university hospitals, while the thresholds were slightly deteriorated after the surgery in 
central hospitals. The 16 operations performed by one surgeon were performed 
between 1993 and 2002, when OI-related hearing loss was studied in Finland (I-IV). 
All these patients were known to suffer from OI, while in thirteen out of the 27 
operations in central hospitals and other university hospitals, the patients were treated 
as patients with the far more common otosclerosis.  
 
The standard of care of patients with such a rare and complicated disease as OI would 
greatly benefit from centralization to a few national centers. Unfortunately, in Finland, 
this has only partly been achieved in OI. The same situation has also concerned the 
treatment of otological problems of OI. The detection of hearing impairment may be 
delayed. The mild forms of OI may be treated as otosclerosis. Our study indicates that 
the surgical outcome is better at departments of otology in the university hospitals 
than at local central hospitals with a smaller annual number of otosclerosis surgery, 
and even fewer patients with OI-related hearing loss. A correct preoperative 
differential diagnosis of OI-related hearing loss and otosclerosis is a prerequisite for 
successful surgery. In addition to more experienced surgeons, different operative 
results may be explained by the anatomical peculiarities in the middle ear in OI 
causing technical problems in an operation unit without laser, that facilitates stapes 
surgery (McGee 1983; Rauch et al. 1992).  
 
6.6. Molecular pathology and genotype-phenotype analysis (V) 
 
The molecular genetic defect was searched for in a selected patient sample of 54. A 
disease causing mutation was found in 49 patients. Altogether, 47 mutations were 
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detected. Forty-one of these mutations are presented for the first time. The 49 patients 
represent the molecular genetic background of 41.1 % of the known Finnish OI 
population.  
 
Mutations reducing the amount of type I collagen are reported to produce the mildest 
phenotypes, while mutations altering the structure of type I collagen produce a wide 
range of phenotypes (Byers 2002; Byers et al. 1991). The association between the 
mutation type and the OI type was also evident in this study. Null allele mutations 
most often produced OI type I, while single base substitutions resulting in glycine 
substitutions in proa2(I) tended to produce OI types I and IV. Furthermore, patients 
with COL1A1 mutations more often had blue sclerae, whereas patients with COL1A2 
mutations tended to be shorter.  
 
Hearing loss has been suggested to be more common in patients with COL1A1 
mutations than in patients with mutations in COL1A2 (Sykes et al. 1990). In this 
study, hearing loss was slightly more common (65.3%) than that previously observed 
in Finnish OI adults (II). Thirty-eight mutations were found in COL1A1 and eleven 
mutations in COL1A2. No correlation between the mutated gene and hearing pattern 
was found.  
 
A variety of mutations causing OI have been identified in COL1A1 and COL1A2 
(Byers et al. 1991; Kuivaniemi et al. 1997; Willing et al. 1996). We found 16 single 
base mutations causing glycine substitution, 16 RNA splicing mutations and 17 null 
allele mutations. The types of mutations did not correlate with the presence, type, 
severity or special characteristics of hearing loss. On the contrary, the different 
mutation types resulted in overlapping hearing phenotypes. Two patients with the 
same null allele mutation in COL1A1, c.299insC, had different hearing patterns 
(patients 42 and 45 in V, Table 2). Patient 42 had normal hearing at 56 years, while 
patient 45 already had a moderate mixed/sensorineural hearing loss (right/left ear) at 
the age of 17 years. On the other hand, both patients with the R848X COL1A1 
mutation had hearing loss that was conductive in patient 41 at the age of 39 years, and 
mixed in patient 46 at the age of 50 years.  
 
In five patients with clinically confirmed OI, no mutation was found in COL1A1 or 
COL1A2 genes by CSGE analysis or sequencing of all exons. The sensitivity and 
specificity of the CSGE mutation search method used in the study are high (Ganguly 
2002; Leung et al. 2001). These five patients may have had large gene rearrangements 
that could not be detected by the mutation detection approach used. On the other hand, 
they may also demonstrate the heterogeneity of OI.  
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7. Conclusions 
 
In the present study on the Finnish Osteogenesis imperfecta (OI) population, 
audiometric findings, results of stapes surgery, and search for molecular defects with 
genotype-phenotype correlation analyses were investigated. In addition, vestibular 
problems in a subpopulation of Finnish adults were studied. The following 
conclusions could be drawn: 
 
 
- Hearing loss is a common feature in OI, affecting patients with all types of OI. 
Of the adults, 57.7% had hearing loss. Patients with OI type I or III may have 
more hearing loss than patients with OI type IV, although the difference was 
not statistically significant in this study. In addition, sensorineural hearing 
loss, especially at an early age, may be more common in OI type I. 
 
- Although hearing loss most often presents in adulthood, it may gradually 
begin already in childhood. Misleading subjective assessment of hearing 
ability in adults with OI emphasizes the importance of regular audiometric 
studies in all patients with OI. While early detection and treatment of hearing 
loss with middle ear surgery and hearing aids are of utmost importance to 
avoid aggravation of physical handicap, audiometry and tympanometry should 
be performed in all OI patients as a baseline study at the age of 10 years with 
repeated audiograms every third year thereafter, even in asymptomatic 
patients.  
 
- Vertigo is common in OI. Of the adults, 52.4% had vestibular dysfunction. 
Inner ear damage appears to be the main reason for vertigo, but basilar 
impression of the skull (BI) may cause vertigo in some patients. Still, some OI 
patients without hearing loss or BI suffer from vertigo clinically 
indistinguishable from the type of vertigo seen in patients with hearing loss or 
BI. In clinical practise, patients with OI should be informed about the 
frequency of vertigo in OI, which is not only a symptom of BI, a feared 
complication of OI.  
 
- The surgical anatomy in OI differs from otosclerosis especially in the thick 
and vascular mucosa with excessive bleeding tendency, a thick, often 
obliterating stapes footplate formed by abnormal bone and elastic, fractured or 
atrophic stapes crura. The anatomical peculiarities in the middle ear in OI 
cause technical problems, and therefore, a prerequisite for successful surgery 
is a correct preoperative differential diagnosis of OI-related hearing loss and 
otosclerosis. Furthermore, the hearing gain appears to be better after surgery 
centralized in units with a larger annual number of otosclerosis surgery and 
more experienced surgeons. 
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- COL1A1 mutations are more frequent in OI types I and III, and COL1A2 
mutations in OI type IV. Furthermore, null allele mutations most often 
produce OI type I, while single base substitutions resulting in glycine 
substitutions in proa2(I) tend to produce OI types I and IV. However, neither 
the mutated gene nor the type of mutation correlated with the presence, type 
or severity of hearing loss, the age at onset of the hearing loss, or special 
features of the hearing loss such as early sensorineural hearing loss or the 
expression of hearing loss in the family. No mutation in COL1A1 or COL1A2 
genes was found in five of the 54 patients with clinically confirmed OI. This 
may be due to large gene rearrangements not detectableby the mutation 
detection approach used, or may demonstrate the heterogeneity of OI.   
Acknowledgements 
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